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Aim of the thesis
11
Chronic liver damage of various origins (e.g. viral hepatitis; chronic intoxication
by alcohol, chemicals or drugs; Wilson’s disease) can eventually lead to liver
cirrhosis, the end stage of liver fibrosis. This process is characterized by the
accumulation of excessive amounts of scar tissue within the liver. The hepatic stellate
cell (HSC) plays a crucial role during this fibrotic process. After liver damage, this
cell-type becomes activated and starts to proliferate, during which it transforms from
a resting vitamin A-storing cell into an activated myofibroblast-like cell. This activated
HSC produces excessive amounts of extracellular matrix compounds and inhibitors
of matrix degradation, thereby strongly affecting the liver architecture and hepatic
organ function. Up till now, no pharmaceutical intervention is available to treat this
fibrotic disease, leaving liver transplantation as the only option left.
Animal model studies revealed however that this fibrotic process is reversible.
Livers can undergo regression of fibrosis after withdrawal of the damaging stimulus,
even in an advanced stage of cirrhosis. This regression was found to be
accompanied by the disappearance of activated HSC via apoptosis. This important
observation suggests that inducing or accelerating HSC apoptosis during
fibrogenesis might attenuate or reverse the fibrogenic process. However, the
therapeutic application of these apoptosis-inducing drugs might be troublesome
because these drugs do not accumulate at the target cell in the diseased liver and
therefore may cause side effects elsewhere in the body. A drug-targeting approach in
which the chosen drug is specifically delivered in the HSC may therefore be highly
relevant for apoptosis-inducing drugs. Such an approach would lead to increased
accumulation of the drug at the desired site, but it may also reduce the adverse
effects after systemic administration of the targeted drug.
The aim of this research project was therefore to examine the possibility of
HSC-specific induction of apoptosis. A drug targeting construct, capable of selective
delivery of apoptosis-inducing drugs to the HSC during liver fibrosis was developed.
The HSC-selective drug carrier mannose-6-phosphate-modified human serum
albumin (M6PHSA) was used in these studies. This carrier was designed to
specifically bind to insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P)
receptors, which are upregulated on the cell surface of activated HSC. As apoptosis-
inducing drugs, we applied gliotoxin and 15-deoxy-Δ12,14-prostaglandin J2. Both drugs
were chosen because of their potent ability to induce apoptosis in HSC, yet their










The liver in a historical context
The role of the liver as one of the three principle organs of the body, together
with the heart and the brain, has been proposed by several ancient medical
practitioners. It was the Roman anatomist Galenus (ca 200 AD, Figure 1) who
pinpointed the liver as the principle organ in the human body. He argued that in the
liver, the blood was formed. Also, the liver was regarded as the center of the
circulation of material substances in the body. The connection of the liver with the
heart resulted in a small mix of blood with the spirit in the arteries 1.
Galenus saw the gall bladder and the spleen as two crucial subsidiary organs
of the liver. This system produced and stored three of the four humors of the body. In
the classical theory within the physiology was the state of health and character of an
individual person was dependent upon a balance between four elemental fluids:
blood (liver), yellow bile (gall bladder), black bile (spleen) and phlegm 1.




The liver structure and function
Today, we know that the liver is the largest internal organ of the human body
(about 5 % of the total body weight) and comprises four different hepatic cell types:
Hepatocytes, Endothelial Cells, Kupffer Cells and Hepatic Stellate Cells (Figure 2).
Figure 2: Scanning electron microscopic pictures of the liver. A: The liverlobule. (VC: Central Vein). B:
Detail of the liver lobule (He : Hepatocyte). C: Detail of the fenestrated sinusoid (Fe: Fenestra). D: The
cells in the sinosoid (RBC: Red Blood Cell, KC: Kupffer Cell. The arrow might indicate a Hepatic
Stellate Cell) From: Tissues and Organs: a text-atlas of scanning electron microscopy (1979) Kessel





The liver is involved in the metabolic homeostasis of the body. This, among
many other processes, includes the lipid metabolism and synthesis of bile salts. Also,
the detoxification of a spectrum of products in the blood and the excretion of
endogenous substrates and xenobiotics into bile are performed by the liver. The liver
synthesizes many proteins circulating in the plasma, such as albumin, acute phase
proteins and clotting factors while it also provides a storage pool for vitamins, iron
and copper. Carbohydrate metabolism and regulation of blood glucose levels is also
a major function of the liver.
Liver Fibrosis
Liver fibrogenesis is initiated by chronic hepatocyte damage which can be
caused by chronic alcohol abuse or other toxic injuries, viral hepatitis, hepatocellular
carcinoma, metabolic liver disorders, biliary cholestasis or autoimmune diseases.
Liver fibrosis is the result of an impaired wound-healing response of the organ
to restore homeostasis after the repeated hepatic injury. After hepatocyte damage,
the hepatocytes regenerate, to replace the cells that are lost (via necrosis or
apoptosis). This response is associated with the release of pro-inflammatory
cytokines and the deposition of extra cellular matrix (ECM) components. Chronic liver
injury eventually leads to impaired regeneration and hepatocytes are increasingly
replaced by the abundantly synthesized ECM products. The normal composition of
the ECM also changes from basement membrane-like matrix to an interstitial type of
matrix. This interstitial matrix is composed mainly of collagen types I and III. Also the
degradation of ECM is affected by the fibrotic process. A group of enzymes
specialized in the removal of ECM, Matrix Metalloproteinases (MMP) are upregulated
during the fibrotic process, but the function of the MMPs is largely suppressed by the
overexpression of the inhibitors of these MMPs (Tissue Inhibitors of MMP, TIMP). So
during the course of fibrosis, more ECM is degraded but even more ECM is
deposited 2.
Cirrhosis, the end state of the fibrotic process, is characterized by dramatic
accumulation of ECM in the liver resulting in nodule formation. As a consequence,
this causes a complete distortion of the normal liver architecture and a high
resistance for a normal blood flow within the liver. This ultimately leads to a




Liver diseases are a growing problem in the Western world. Up till now, liver
related diseases represents the 10th leading cause of death in the United States 4.
The last two decades, there has been a steady increase in the number of liver-related
deaths due to hepatitis C infection and obesity associated diseases (Non-alcoholic
steatohepatitis, NASH), suggesting a higher mortality ranking in the future 5. One of
the major problems in liver diseases is that patients having liver diseases are mostly
asymptomatic for a long time. Only after a latency period (10-15 year) the first stages
of fibrosis are detectable. The golden standard for the detection of liver fibrosis is via
a liver biopsy. This histology-based method is not without risk for the patient and
considerable diagnostic errors can occur due to a limited number of small biopsies.
The lack of an easy, safe and reliable non-invasive assessment of liver function
makes it difficult to detect fibrosis in an early phase and complicates the monitoring of
potential effects of therapeutic interventions 6,7.
The current treatment of liver fibrosis generally consists of the removal of the
causative agent. This strategy has proven to slow down or even stop the fibrotic
process. Unfortunately, a large group of patients does not respond to this therapy
(i.e. removal of the inciting stimulus does not stop the fibrotic process). For these
patients, the only treatment left is a liver transplantation. This rigorous and costly
intervention, if available, will cause a life long medicine use and a relatively high risk
of failure.
The fibrogenic hepatic stellate cell
The Hepatic Stellate Cell (HSC) has been identified as a key mediator in this
ongoing fibrotic process. The HSC are located in the space of Disse and this cell type
comprises 5-8% of the total number of cells in the liver. In a quiescent state, these
cells, characterized by their long cellular extensions, are essential for the
maintenance of liver architecture and the regulation of blood flow. These quiescent
HSC also contain the largest quantity of vitamin A in the body 8. Upon liver injury, the
HCS undergo a phenotypical transformation from a quiescent to an activated
myofibroblasts-like cell. These activated HSC loose their vitamin A, start to
proliferate, release several pro-inflammatory cytokines and produce the previously
discussed excessive amounts of collagens, leading to scar tissue deposition and
nodule formation in the liver (Figure 3) 9.
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Figure 3: The transformation of the hepatic stellate cell into myofibroblast-like cells. Following liver
injury, hepatic stellate cells become activated. This initiates the transformation from quiescent vitamin
A-rich cells into proliferative and fibrogenic myofibroblasts (From S. L. Friedman, Molecular regulation
of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275(4):2247-
2250).
Reversion of liver fibrosis
For a long time, researchers thought that advanced liver fibrosis was
irreversible. However, published data from animal models for liver fibrosis point out
that this fibrotic process is quite reversible, even in a late stage of the disease.
One model of cholestatic liver fibrosis, in which the bile duct of the rat liver is
ligated, results in a severe form of biliary fibrosis with extensive bile duct proliferation
in the portal zone of the liver 10. A biliojejunal anastomis of rats with established liver
fibrosis appeared to result in a resolution of fibrosis within a 6 week period 11,12.
Another fibrosis model comprises a 4 week treatment with the liver toxic agent CCl4
which results in parenchymal liver fibrosis. Withdrawal of the CCl4 resulted in a
spontaneous resolution of rat liver fibrosis 13. Even established nodular cirrhosis
underwent a near complete resolution after terminating the injury 14.
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Patients with liver fibrosis due to chronic hepatitis C also showed a reduction
in the progression of liver fibrosis and even in some cases reversal of cirrhosis after
treatment with pegylated interferon alfa-2b and ribavirin 15.
The fate of the HSC during resolution of liver fibrosis
The fibrotic process involves both major proliferation as well as activation of
HSC. During the resolution of fibrosis, the activated HSC population decreases to the
level found in normal livers. Consequently, the HSC can reverse to a quiescent state
or can undergo apoptosis (Figure 4).
Figure 4: The resolution of liver fibrosis. The fate of activated stellate cells during resolution of liver
injury is unknown but may include reversion into quiescent cells and/or selective clearance by
apoptosis (From S. L. Friedman, Molecular regulation of hepatic fibrosis, an integrated cellular
response to tissue injury. J Biol Chem 2000; 275(4):2247-2250).
The reversion of activated HSC to quiescent HSC has been reported in
cultures in which activated HSC were re-cultured on Matrigel 16. However, data
confirming reversal of activated HSC in vivo are lacking.
The reduction of activated HSC by apoptosis has also been confirmed in vivo
during the resolution process 13,14,17. Apoptosis, or programmed cell death, is a form
of cellular suicide that is widely observed in nature. Unlike necrosis, apoptosis of cells
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is well orchestrated and ultimately results in the fragmentation of the cell in small
membrane surrounded particles. These so-called apoptotic bodies can subsequently
be removed by phagocytosis. Apoptosis plays an important role during embryonic
development and tissue homeostasis. A dysfunctioning in the strict regulation of the
apoptotic process is thought to play a role in the pathogenesis of a wide variety of
diseases including cancer 18. A hallmark of apoptosis is the activation of various
intracellular proteases, called caspases. These caspases are already present in the
cytoplasm of each cell in the form of inactive procaspases. After cleavage of these
procaspases, activated caspases are able to cleave several critical intracellular
peptides ultimately leading to the destruction of the cell 19.
There are two main apoptotic pathways. The first pathway involves cell-
surface death receptors. Upon ligand binding, these receptors activate their
intracellular death domain, activating the caspase cascade. The best characterized
death receptor is CD95, also known as FAS, or Apo1 20. The second apoptosis
pathway involves mitochondria, where a disruption of the electron transport system,
release of apoptosis-regulating proteins and alterations of the cellular reduction-
oxidation potential can trigger caspase activation, ultimately leading to apoptotic cell
death 21.
Potential therapeutic intervention: stimulation of HSC apoptosis
As argued above, the induction and acceleration of HSC apoptosis during
fibrosis may be a strategy for the treatment of liver fibrosis 17,22. This has led to the
discovery of several compounds that were able to induce HSC apoptosis in vitro 23-29.
Gliotoxin and 15-deoxy-Δ12,14-Prostaglandin J2 are two examples of such compounds
that induce apoptosis in HSC 24,27.
An alternative strategy involves the inhibition of apoptosis of the hepatocytes
rather then inducing apoptosis in HSC. For example, the compound IDN-6556
reduces the formation of apoptotic bodies, which reduces the inflammatory response




Gliotoxin (GTX) is a member of the epipolythiodioxopiperazine class of fungal
metabolites (Figure 5). GTX is a natural product of the fungus Gliocladium fimbriatum
31
, but also other fungus species can produce this metabolite 32. GTX attracted more
attention after the discovery of its antibacterial and antiviral properties 33, but the
awareness of its in vivo toxicity limited the use of this compound as a therapeutic
agent 34.
Figure 5: The chemical structure of Gliotoxin
GTX displays immune suppressive effects and promotes apoptosis in several
cell types including thymocytes, macrophages, lymphocytes, enterocytes and various
other cell lines of different origin 32,35-37. This compound also promotes apoptosis in
human and rat HSC in vitro. In addition, it reduces hepatic fibrosis through HSC
apoptosis while leaving the hepatocytes intact in the rat CCl4 fibrosis model 27.
The mechanism by which GTX induces apoptosis is still unknown. However,
GTX has been shown to inhibit the action of nuclear factor țB (NFțB)35. NF-țB is a
transcription factor that plays a central role in the immune response 38, which could
also explain the immunosuppressive effect of GTX 35.
Recently, NF-țB independent HSC apoptosis induced by GTX has been
reported. In one scenario, GTX induces reactive oxygen species (ROS)-mediated
apoptosis. This pathway involves induction of mitochondrial permeability transition
(MPT) and release of cytochrome C 39. A second study claimed the involvement of
the adenine nucleotide transporter (ANT), a mitochondrial membrane protein, which




Prostaglandins are a family of biological active polyunsaturated fatty acids
containing a backbone of 20 carbon atoms. The general pathway for the biosynthesis
of prostaglandins is illustrated in figure 6. First, arachidonic acid is released from
membrane phospholipids by the enzyme phospholipase A2. Then, arachidonic acid is
converted to Prostaglandin H2 (via Prostaglandin G2) by the enzymes
cyclooxygenase 1 and 2 (COX-1 and -2). COX-1 is a constitutive form of the enzyme,
whereas COX-2 is highly inducible by proinflammatory cytokines. Prostaglandin H2 is
the precursors for all other prostaglandins, prostacyclin and thromboxane 41.
Prostaglandin D2 can further be converted to ProstaglandinJ2 and 15-deoxy-Δ12,14-
Prostaglandin J2 (15d-PGJ2) by dehydration (Figure 7) 42. Within the prostaglandin
family, the A and J types contain a highly reactive cylopentenone ring structure,
which can ligate to nuclear receptors and signaling molecules 43,44.
The interest in 15d-PGJ2 was raised after two independent discoveries that
this compound acted as a high affinity ligand for the peroxisome proliferators-
activated receptor Ȗ (PPARȖ) 45,46. The PPAR family consists of three isoforms,
PPAR-Į, PPAR-ȕ and PPAR-Ȗ 47-49. PPARs belong to the nuclear receptor super
family and they regulate gene expression associated with lipid homeostasis,
inflammation, cell proliferation and malignancies 50.
Recently, it was shown that 15d-PGJ2 induced apoptosis in human hepatic
myofibroblasts (hMf, a HSC model by outgrowth of human liver tissue). At sub-
apoptotic concentrations, the proliferation of hMF was effectively inhibited together
with a strong reduction in the expression of collagens 51 and an increase in Heme
Oxygenase 1 (HO-1) expression 52,53. The upregulation of HO-1 expression during
liver fibrosis could be a major antifibrotic pathway 3,52,53. Direct evidence supporting
this theory was found with HO-1 knock-out mice. These mice eventually develop liver
fibrosis 54.
15d-PGJ2 was found in vivo at sites of inflammation during the resolution
phase of fibrosis, suggesting that it might function as a negative feedback regulator of
the inflammatory process since the anti-inflammatory effect of 15d-PGJ2
downregulates the COX-2 enzyme, crucial for the biosynthesis of 15d-PGJ255,56. 15d-
PGJ2 induces apoptosis of endothelial cells via the PPAR dependent pathway 57.
However, the mechanism by which 15d-PGJ2 induces apoptosis of hMF remains
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clear. This pathway involves oxidative stress and is not mediated by PPARȖ, since
this nuclear receptor is not expressed in hMF 24.
Figure 6: Pathway of the biosynthesis of prostaglandins. Membrane phospholipids are transformed to
arachidonic acid, which in turn is converted to Prostaglandin H2, the central prostaglandin precursor.
PGH2 can then be converted to all other prostaglandins, prostacyclin or tromboxane (From D. S.
Straus, C. K. Glass. Cyclopentenone prostaglandins: New insights on biological activities and cellular
targets. Medicinal Research Reviews 2001; 21(3):185-210).
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Figure 7: The sequential conversion of the cyclopentenone PGD2 to 15d-PGJ2 (From D. S. Straus, C.
K. Glass. Cyclopentenone prostaglandins: New insights on biological activities and cellular targets.
Medicinal Research Reviews 2001; 21(3):185-210).
IDN-6556
A recent development in the therapeutic treatment of liver fibrosis is not to
induce HSC apoptosis, but to inhibit apoptosis in hepatocytes 58. Hepatocyte
apoptosis is a major characteristic of liver injury resulting in fibrosis 59,60.The
hepatocytes-originated apoptotic bodies are removed by phagocytosis 61. It has been
shown that also HSC express the machinery necessary to phagocytose apoptotic
bodies. The in vitro phagocytosis of apoptotic bodies by HSC causes activation of
HSC, and as a result, pro-fibrotic stimuli are produced 62. The caspase-inhibitor IDN-
6556 effectively reduces hepatocyte apoptosis in a BDL mouse model of liver
fibrosis. This results in a reduction of HSC activation and attenuation of liver fibrosis
30
. This successful compound is the first caspase inhibitor to enter phase II clinical




The use of drugs that regulate apoptosis for the treatment of liver fibrosis
might be full of risk. The action of such drugs is only preferred at the desired site and
general effects elsewhere in the body may cause serious side effects.
The disadvantage of gliotoxin
Gliotoxin has not only been studied because of its anti-fibrotic activities. The
apoptosis-inducing compound also effectively attenuated dextran sodium sulfate-
induced colitis in rats. This seemed to be associated with a systemic
immunosuppressive effect of GTX. However, this broad immunosuppressive effect
appeared to seriously affect the viability of the experimental animals 65. For mice, the
50% lethal dose (LD50) of GTX was found to be 10 mg/kg. In this same study, it was
demonstrated that intra-peritoneal injections of GTX also caused apoptosis in the
thymus, spleen and mesenteric lymph nodes. This apoptotic effect was possibly a
direct action of the toxin, since relatively low concentrations of GTX were measured
in these organs 66. Based on the non-specific effect of GTX within the liver 67 and the
uptake in other organs, it remains to be established whether the net effect of GTX
during chronic treatment for liver fibrosis is beneficial 67.
The disadvantage of 15-deoxy-Δ12,14-Prostaglandin J2
15d-PGJ2 exhibits various effects including growth arrest, apoptosis induction,
anti-pyretic effects and suppression of macrophage activation 24,55,68,69. The
therapeutic use of the lipophilic compound 15d-PGJ2 is limited because of the lack of
cell and tissue specificity, resulting in a low efficacy and a high risk of potential side
effects. In general, all prostaglandins are locally acting mediators that are rapidly
metabolized by the lung 70 and cleared from the body by the kidneys, resulting in a
very short half life. For example, PGE2 (dinoprostone) has a plasma half-life (t½) of
less than 1 minute and PGI2 (epoprostenol) has a t½ of 2-3 minutes 71,72. Also, the
high plasmaprotein binding of prostaglandins 73 and the rapid metabolism of
prostaglandins by serum components (i.e. albumin) 42 prevent compounds such as




The disadvantage of IDN-6556
As stated earlier, the introduction of drugs that inhibit the apoptosis process
might introduce severe adverse effects. A treatment with IDN-6556 might not only
inhibit apoptosis in hepatocytes, but also elsewhere in the body. Tissue homeostasis
can be disturbed which may involve an intolerable risk of carcinogenesis and growth
abnormalities after a long-term treatment. The outcome of clinical phase II trials with
IDN-6556 should provide more insight in the potential application in humans 74,75.
Conclusions
The growing knowledge on how apoptosis is regulated in normal tissue and,
even more relevant, is deregulated in several forms of cancer has resulted in the
introduction of drugs that specifically regulate the apoptosis pathways. Some of these
drugs already entered clinical trials and may eventually alter the whole cancer
therapy treatment 76. Liver fibrosis, where the control of tissue repair is lost due to the
abundant presence of activated HSC, is also a disease where drugs interfering with
apoptosis might be beneficial. However, general apoptosis should not occur or
should be minimized. Cell-selectivity is therefore a crucial element in this strategy.
The specific delivery of drugs to the HSC may be an attractive strategy to design a
treatment for liver fibrosis. Drug targeting alters the biodistribution profile of a drug,
resulting in an accumulation of the drug at a specific site in the body, while it limits
the adverse effects elsewhere 77.
Cell-selective targeting can be accomplished by various drug delivery systems,
including liposomes, polymers, nanoparticles, antibodies, and carrier proteins 78-82.
Cell selectivity can be largely improved by coupling a specific homing device to such
a carrier system. The drug of interest can be incorporated in liposomes and
nanoparticles, or covalently attached to polymers, antibodies and protein carries to
obtain a cell-selective drug carrier construct.
Recently, HSC-specific drug delivery systems have been developed. These
carriers have Human Serum Albumin (HSA) as the protein backbone. The coupling of
more than 20 molecules of the sugar Mannose-6-Phosphate (M6P) gives the carrier
specificity for the Insulin like Growth Factor II/Mannose-6-Phosphate receptor
(IGFII/M6P), abundantly found on activated HSC 83,84. Specific peptide sequences
recognizing the PDGF-receptor or the Collagen IV receptor that are also
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overexpressed during liver fibrosis also have been attached to the albumin core to
obtain HSC selectivity 78,85,86.
Preliminary studies using the HSC-specific carrier (M6P-HSA) coupled to
doxorubicin, losartan, pentoxyfilline and mycophenolic acid resulted in a successful
delivery of the drug to the HSC. Recent in vivo effect studies showed a reduction in
the level of fibrosis in rats with established liver fibrosis. Also the side effects were
reduced compared to the non-targeted drug 87-90.
Since the use of apoptosis-inducing drugs might benefit from a drug targeting
approach, studies that couple GTX and 15d-PGJ2 to HSC-selective drugs carriers are
warranted.
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Liver fibrosis is the common response to chronic liver injury, ultimately leading
to cirrhosis. Several lines of evidence indicate that inducing apoptosis of Hepatic
Stellate Cells (HSC) may lead to regression of liver fibrosis. Recently, it was shown
that gliotoxin (GTX) induces apoptosis of HSC. However, the clinical use of GTX may
be limited due to the lack of cell and tissue specificity, causing a high risk of
potentially severe adverse effects. The aim of this study therefore, was to study the
effect of GTX on different cells of the liver. We used normal and fibrotic precision-cut
rat liver slices to study the effect of GTX on the various resident liver cell types. In
these slices, the complex cell-cell interactions are preserved, which closely mimics
the in vivo situation. GTX exhibited a potent apoptosis inducing activity in these
slices. Both immunohistochemical stainings and real-time mRNA techniques showed
that this apoptosis-inducing effect was seen in HSC. However, Kupffer cells and liver
endothelial cells were also affected by GTX, whereas hepatocytes were only mildly
affected. This study indicates that the apoptosis-inducing strategy to treat liver
fibrosis has high potential, but it will be necessary to develop an HSC-specific
therapy to avoid adverse effects.
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INTRODUCTION
Chronic liver injury leading to liver fibrosis can occur in response to different
forms of injuries, including alcohol abuse, drugs, viral hepatitis, and autoimmune
diseases 1. During liver fibrosis, the hepatic stellate cell (HSC) plays a crucial role.
After hepatocyte damage, this cell-type becomes activated and starts to proliferate.
During this activation process, the HSC transforms from a resting vitamin A-storing
cell into an activated myofibroblast-like cell and produces extensive amounts of scar
tissue. Eventually, the end stage of fibrosis, cirrhosis, may be reached 1.
In experimental animal models for liver fibrosis, the fibrotic process seems
quite reversible. Even in an advanced fibrotic state (i.e. after 4 weeks treatment with
carbon-tetrachloride [CCl4]) withdrawal of the fibrotic stimulus leads to restoration of
the normal hepatic structure. This resolution of fibrosis was accompanied by the loss
of activated HSC via spontaneous apoptosis 2. Recently, it has been shown that end
stage liver cirrhosis (12 week CCl4) can also undergo incomplete spontaneous
recovery after terminating the fibrotic stimulus. Again, this was associated with
induction of apoptosis in HSC 3.
The fungal metabolite Gliotoxin (GTX), a member of the epipolythiodioxo-
piperazine family, promotes apoptosis in human and rat HSC in vitro. In addition, it
reduces hepatic fibrosis through HSC apoptosis while leaving the hepatocytes intact
in the rat CCl4 fibrosis model 4. However, GTX also displays immune suppressive
effects and promotes apoptosis in several different cell types including thymocytes,
macrophages, lymphocytes, enterocytes and several other cell lines of different
origin5-8, which may induce serious side-effects if GTX would be used as an anti-
fibrotic drug.
To further investigate GTX as a potential anti-fibrogenic drug, it should be
established whether other cells than activated HSC are affected by this drug. The
effect of GTX on other non-parenchymal liver cells has not been examined in
previous studies. Adverse effects of GTX on Kupffer cells and endothelial cells in the
liver or on cells of the immune system could limit a successful application of this
apoptosis-inducing strategy for the treatment of liver fibrosis in the future.
The aim of this study was to determine the specificity of effects of GTX within
the liver. We therefore used precision-cut rat liver slices prepared from normal as well
as fibrotic livers to study the specificity of GTX on various resident liver cells. In these
slices, the complex cell-cell interactions are preserved, mimicking the in vivo situation
9,10
. Moreover, this test system allows examination of the direct effects of GTX on




Animals and animal model
Specific pathogen-free male Wistar rats, purchased from Harlan (outbred strain, Horst, The
Netherlands), were used in this study. The rats received a standard diet and were housed under
standard laboratory conditions. To induce liver fibrosis, rats were subjected to bile duct ligation (BDL)
as described by Kountouras et al. 11 under anesthesia with 40% O2 : 60% N2O combined with 0.5%
isoflurane (Abbot Laboratories Ltd, Queensborough, Kent, UK). Three weeks after the ligation (BDL3),
rats were used for further experiments. Untreated, normal animals served as the control group. The
study as presented was approved by the local committee for care and use of laboratory animals and
was performed according to strict governmental and international guidelines on animal
experimentation.
Liver slices
Precision-cut liver slices were prepared from normal (n=3) and BDL3 (n=3) rats 9. After
sacrificing the rats, the livers were taken out and stored in ice-cold University of Wisconsin
preservation solution (UW) until preparation of the slices using the Krumdieck tissue slicer. After
preparation, the slices were stored in UW on ice until use. Slices were pre-incubated for 2 hours in
William’s Medium E (GIBCO, Life technologies LTD, Paisley, Scotland) supplemented with D-glucose
(25 mM) and gentamycin (50 μg/ml) and saturated with 95% O2, 5% CO2 at 37 °C. Slices were
transferred into fresh medium and incubated individually in 6-well plates with different concentrations
(0.1, 1 and 10 μM) of Gliotoxin (GTX; Sigma-Aldrich, St. Louis, MO, USA, diluted in DMSO, 1mg/ml).
Each measurement was performed on three slices. After 8 hours of incubation, the liver slices were
snap-frozen in liquid N2 for the active caspase-3 assay and quantitative real-time PCR analysis, or
frozen in isopentane (-80 °C) for immunohistochemical analysis.
Apoptosis
Three slices from each group were homogenized in caspase lysis buffer (according to the
fluorimetric caspACETM assay system, Promega, Madison, WI, USA) with a sonicator for 15 seconds.
A protein assay was performed (BioRad Laboratories, Hercules, CA, USA) on these homogenates
according to standard procedures. Active caspase-3 was measured in 75 μg (normal slices) or 25 μg
(fibrotic slices) total protein with the fluorimetric caspACETM assay system (Promega), incubated for 60
min at 37 °C according to the instructions described by the manufacturer.
TUNEL assay
Cryostat sections (4 μm) of the liver slices were fixed in 4% paraformaldehyde and apoptotic
cells were stained with a TUNEL staining kit according to the manufacturers procedure (Roche
Diagnostics, Indianapolis, IN, USA). The negative control for each slice consisted of adding the label
solution only, ommiting the terminal transferase. Additionally, all sections were stained with DAPI
staining solution (Roche Diagnostics) to visualize all nuclei. Sections were analyzed with a
fluorescence microscope (magnification 200X).
HSC isolation
Primary HSC were isolated from livers of male Wistar rats (450-550g) according to Geerts et
al. 12. The liver was digested with collagenase P, DNAse (both Roche Diagnostics) and pronase
(Merck KGaA, Darmstadt, Germany). After separation of the HSC from other hepatic cells by density-
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gradient centrifugation, the HSC were collected at the top of an 11% Nycodenz-solution.
Subsequently, the cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM, GIBCO, Life
technologies LTD) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 μg/ml
streptomycin and incubated in a 5% CO2 humidified atmosphere at 37 °C. Cells cultured for 7 days
were used for further experiments. During the growth period, the HSC transforms from a quiescent cell
to an activated myofibroblast. The cells were daily observed and the presence of Į-Smooth muscle
actin (Į-SMA) was confirmed by immunohistochemical staining cells.
Viability assay
HSC were seeded sub-confluent in 96 well culture plates and cultured for one day with serum
(described above), then washed with serum-free medium and incubated for 24 hours in 200 μl medium
without serum. Subsequently, GTX was added in various concentrations and the cells were incubated
for another 18 hours. Alamar blue (20 μl, Serotec, Oxford, UK) was added and the cells were
incubated for an additional 8 hours (24 hours for HSC). The conversion of the Alamar blue REDOX
indicator by metabolic activity of each cell reflects the viability of the cells present in each well and can
be measured using a fluorimeter. Control incubations without cells did not show an affect of GTX on
alamar blue 13.
Immunohistochemical stainings
Acetone-fixed cryostat sections (4 μm) of liver slices were stained using indirect
immunoperoxidase methods according to standard procedures 14. All HSC were detected with the
simultaneous staining of two mouse monoclonal primary antibodies for the presence of desmin (II) (MP
Biomedicals, Irvine, CA, USA) and glial fibrillary acidic protein (GFAP, Neomarkers, Fremont, CA,
USA) 14. Detection of endothelial cells was performed with the mouse monoclonal antibody RECA-1
(Serotec). The mouse monoclonal antibody ED2 (Serotec) was used as a specific marker to detect the
presence of Kupffer cells within the sections. The goat polyclonal antibody against rat collagen type III
(Southern Biotech, Birmingham, USA) was used to stain the collagen type III in the liver. Apoptotic
cells were demonstrated by the staining for active caspase-3 using a mouse monoclonal antibody (Cell
Signaling Technology Inc, Beverly, MA, USA). After the primary antibody, sections were stained with a
secondary peroxidase-conjugated rabbit anti-mouse (Desmin/GFAP, RECA-1, ED2) or rabbit anti-goat
(collagen III) IgG (DAKO, Glostrup, Denmark). The RECA-1 staining was further amplified using the
peroxidase-conjugated goat anti-rabbit IgG (DAKO). The peroxidase activity was subsequently
visualized with 3-amino-9-ethylcarbazole (AEC; Sigma-Aldrich) for 20 min. Finally, sections were
counterstained with hematoxylin (Fluka Biochemica, Buchs, Switzerland) and mounted in Kaisers
glycerin-gelatin (Merck). The negative control was performed using the standard staining method 14
omitting the first antibody in the incubation step (PBS alone). Sections were evaluated at a
magnification of 200X.
Periodic acid Schiff (PAS)
Cryostat sections (4 μm) of liver slices were fixed in 4% formalin / methanol, incubated with
periodic acid and stained with Schiff’s reagent (Merck) according to standard methods. The staining of
the sections was quantified with ImageJ software (National Institute of Health, Bethesda, Maryland,
USA). On a digital photo, the total area stained positive for PAS was measured and related to the total
area analyzed per liver slice at a magnification of 40X.
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RNA isolation and reverse transcriptase PCR.
Total RNA was isolated from 3 slices using an RNA isolation kit (Qiagen GmbH, Hilden,
Germany) according to the manufacturers procedure. The amount of RNA was estimated with a
Ribogreen assay (Molecular Probes, Eugene, OR, USA) according to standard procedures. The
reverse transcriptase reaction was performed (Promega) for 10 min at 25°C, 60 min at 45°C, 5 min at
95°C with the random primers.
Real-time PCR
Real-time quantitative PCR was performed with the ABI 7900HT apparatus (Applied
Biosystems, Foster City, CA, USA). cDNA was added in each PCR reaction as well as the SYBR
Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and the forward and reverse
primers (50 pM). The housekeeping gene GAPDH was used as reference gene for normalization and
H2O was used as negative control. Desmin was chosen as a marker for the activated HSC, fucose-
receptor was used as a marker for Kupffer cells, preproalbumin was used as a specific marker for
hepatocytes and e-NOS was chosen as a marker for sinusoidal liver endolthelial cells as well as
endothelial cells from the vessel 12,15. The primers used in the PCR reactions were: rat desmin,
forward, 5’-AGGAACAGCAGGTCCAGGTA-3’, reverse, 5’-AGAGCATCAATCTCGCAGGT-3’ (product
size 250 bp); rat eNOS forward, 5’-TGACCCTCACCGATACAACA-3’, reverse, 5’-
TCTGGCCTTCTGCTCA TTTT-3’, (product size 211 bp); rat fucose receptor, forward, 5’-
AGTCTGAGAGGCGATTTGGA-3’, reverse, 5’-CATCTCTCATGGCCTGGATT-3’, (product size 250
bp); rat preproalbumin, forward, 5’-GAAGCACACAAGAGTGAGATCG-3’, reverse, 5’-
AGTTGTCACGAAGCTTTGGAAT-3’, product size 250 bp); rat collagen type 1 α1 (collagen 1a1),
forward, 5’-AGCCTGAGCCAGCAGATTGA-3’, reverse, 5’-CCAGGTTGCAGCCTTGGTTA-3’, (product
size 145 bp); rat GAPDH, forward, 5’-CGCTGGTGCTG AGTATGTCG-3’, reverse, 5’-
CTGTGGTCATGAGCCCTTCC-3’, (product size 179 bp). The PCR reactions consisted of 40 cycles
(denaturation 15 sec 95 °C, annealing 15 sec 56 °C, extension 40 sec 72 °C). The formation of single
products was confirmed by analyzing the dissociation step at the end of each PCR reaction. Data were
analyzed with the SDS 2.1 software program (Applied Biosystems). The relative amount of the
designated PCR-product was calculated by the comparative threshold cycle (CT) method.
Statistics
Results are expressed as mean ± SD. Statistical analysis was performed by two-tailed
Student’s test. P values lower than 0.05 were considered statistically significant.
RESULTS
Gliotoxin induces apoptosis in precision-cut rat liver slices
To differentiate between the sensitivity of the various liver cells for GTX, we
used precision-cut rat liver slices where all cell types (HSC, hepatocytes, endothelial
cells and Kupffer cells) reside in the context of their natural environment and their
complex cell-cell interactions are preserved 9.
We incubated normal and fibrotic rat liver slices with different concentrations
(0.1, 1 and 10 μM) of GTX and measured induction of apoptosis by assessment of
the caspase-3 activation. In liver slices from normal rat livers, GTX dose-dependently
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increased apoptosis. The maximal fold induction of caspase-3 activation was 5.0 ±
1.8 after an 8 hour incubation with the highest concentration of GTX (10 μM) as
compared to the normal slices incubated with vehicle (i.e. control incubation, Δ
fluorescence units/hour at 37 °C/μg protein changed from 0.6 ± 0.5 [control
incubation] to 3.0 ± 0.9 [10 μM GTX], Figure 1). The response to GTX in fibrotic slices
was significantly higher as compared to normal liver slices; the maximal fold induction
reached 10.2 ± 1.0 after an 8 hour incubation with the highest concentration of GTX
(10 μM) as compared to control fibrotic slices (Δ fluorescence U/h at 37 °C/μg protein
changed from 1.6 ± 0.1 [control incubation] to 21.4 ± 3.5 [10 μM GTX], Figure 1).
Figure 1: Induction of caspase-3 activity by GTX in normal (open bars) and fibrotic (closed bars) liver
slices. Slices were incubated for 8 hours with different concentrations of GTX. The results are
expressed as the mean ± SD (n=3 livers). * indicates a significant difference as compared to control
liver slices (p < 0.05), # indicates a significant difference between normal and fibrotic liver slices
incubated with the same concentration of GTX (p < 0.05).
To visualize induction of apoptosis after incubation with GTX in these slices,
TUNEL and active caspase-3 stainings were performed. Both normal and fibrotic rat
slices showed a strong increase in TUNEL-positive cells after incubation with GTX in
a concentration-dependent manner starting at 0.1 μM GTX. Again, the number of
apoptotic cells in the GTX-treated fibrotic liver slices was higher than in the normal
liver slices (Figure 2). Immunohistochemical stainings of the liver slices with a specific
active caspase-3 antibody confirmed the results of the TUNEL staining (data not
shown). These results clearly show a concentration-dependent induction of apoptosis
by GTX both in normal and fibrotic liver tissue. Furthermore, cells within fibrotic liver










































Figure 2: Representative microphotographs of the simultaneous detection of the nucleus (DAPI
staining) and apoptotic cells (TUNEL staining) of normal and fibrotic liver slices after 8 hours
incubation with different concentrations of GTX. Note the increase in TUNEL-positive cells in the
fibrotic liver slices as compared to the same incubation of normal liver slices (Magnification 200X).
GTX reduces viability of activated primary isolated HSC in vitro
To investigate the response of activated primary isolated rat HSC incubated
with GTX, alamar blue viability assays were performed. HSC are known to go into
apoptosis after incubation with GTX 4. Indeed, we found a dose-dependent decrease
in viability in cultures of activated HSC. A significant decline in viability was already
found at a GTX concentration of 0.1 μM (Figure 3).
Figure 3: Viability of isolated activated HSC incubated with different concentrations of GTX. The
control cells (incubated with vehicle) are set at 100% viability, whereas control wells without cells are
set as 0% viability. The results are expressed as the mean ± SD (n=3). * indicates p < 0.05 compared
to the control activated HSC.
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Figure 4: Immunohistochemical detection of non-parenchymal hepatic cells in control fibrotic slices
(left panel) and fibrotic slices incubated with 10 μM GTX for 8 hours (right panel). A: HSC were
detected with desmin and GFAP antibodies. B: Kupffer cells (KC) were stained with the ED2 antibody.
C: The RECA-1 antibody was used to stain sinusoidal endothelial cells (EC). D: The Collagen III
antibody was used to show the level of fibrosis (Magnification 200X).
Gliotoxin affects all cells in rat liver slices
To examine cell-specific responses of GTX within the liver slice, we performed
immunohistochemical stainings of fibrotic livers with different markers for the resident
cell types in the liver. A clear reduction in the staining of the HSC markers desmin
and GFAP was visible after GTX incubation (Figure 4A). The stellate-shaped cells
were nearly gone after incubation with 10 μM GTX as compared to the control fibrotic







slices. A profound reduction in the number of ED2-positive cells (Kupffer cells) was
also noted in slices incubated with 10 μM GTX as compared to the control fibrotic
slices (Figure 4B). Staining of the liver endothelial cells with the RECA-1-antibody
revealed a slight reduction in the number of RECA-1 positive cells as compared to
the control fibrotic slices (Figure 4C). Staining of collagen III clearly shows the fibrotic
state of the rat liver slices (Figure 4D). Taken together, the staining for all non-
parenchymal cell-markers was significantly reduced after incubation of fibrotic liver
slices with GTX (Figure 4).
To test whether GTX might also affect the parenchymal cells in liver slices,
hepatocytes were visualized by PAS-staining. Hepatocytes rapidly respond to stress
or injury by activation of glycogenolysis leading to a reduced glycogen content which
can be demonstrated by PAS staining 16. The area stained positive for PAS per liver
section was quantified with imageJ software (Table 1). The data show a clear
reduction in the staining for normal liver slices incubated with 10 μM GTX. The PAS
staining in slices originating from fibrotic livers was significantly lower than in normal
liver slices, but even this staining was further reduced by 10 μM GTX. Taken
together, these data show that hepatocytes are also affected by GTX incubation, but
only at the highest concentration used.
Table 1: Results of a morphometric analysis of normal and fibrotic liver slices incubated with different
concentrations of GTX and stained with the PAS staining. The total area stained positive for PAS was
measured and related to the total area analyzed per liver slice.
Normal Fibrotic
Control (%) 41 ± 6 5 ± 1
0.1 μM GTX (%) 37 ± 3 6 ± 1
1 μM GTX (%) 32 ± 8 5 ± 3
10 μM GTX (%) 4 ± 0.1 2 ± 1
To examine the effects of GTX on the mRNA expression levels of cell-specific
markers for the different hepatic cells within the livers, quantitative real-time PCR
analysis on both normal and fibrotic liver slices was performed (Figure 5). The
intrahepatic mRNA level for desmin was selected as a marker for the HSC, mRNA
level for the fucose receptor was chosen as a Kupffer-cell selective marker, the
mRNA level for eNOS reflected a endothelial cell-selective marker, and the mRNA
level for preproalbumin was used as a marker for hepatocytes 12. All mRNA-levels of
these markers were related to the expression of the house-keeping gene GAPDH.
Figure 5 shows that GTX affected the mRNA levels for all non-parenchymal
cells in normal as well as fibrotic liver slices significantly (p<0.05). Compared to
control incubations, mRNA levels for desmin were reduced by 46 ±11% in normal and
Gliotoxin-induced apoptosis in liver slices
45
76 ± 14% in fibrotic liver slices by 10 μM GTX (Figure 5A). mRNA levels for the
fucose receptor were reduced by 64 ± 8% in normal and 81 ± 11% in fibrotic liver
slices (Figure 5B), and mRNA levels for eNOS were reduced by 25 ±15% in normal
and 51 ± 10% in fibrotic liver slices (Figure 5C). The mRNA levels for the hepatocyte-
specific marker preproalbumin were not significantly altered in normal (176 ± 51%)
and fibrotic (152 ± 48 %) liver slices as compared to control incubations (Figure 5D).
These real-time PCR results corroborate the results of the immunohistochemical
stainings and clearly indicate that GTX not only significantly affects HSC, but also
Kupffer and endothelial cells, and that hepatocytes are relatively unaffected.
Figure 5: Effect of different concentrations of GTX on several cell-specific intrahepatic mRNA levels in
normal (open bars) and fibrotic (closed bars) liver slices; A: desmin mRNA levels reflecting the HSC;
B: fucose receptor mRNA as a marker for Kupffer cells (KC); C: eNOS mRNA levels as a marker for
liver endothelial cells (EC); D: preproalbumin mRNA levels as a marker for hepatocytes (PC). The
results are expressed as the mean ± SD (n=3 livers). * indicates a significant difference as compared
to control liver slices (p < 0.05), # indicates a significant difference between normal and fibrotic liver
slices incubated with the same concentration of GTX (p < 0.05).
Effect of Gliotoxin on the intrahepatic collagen 1a1 mRNA expression level
A key parameter during liver fibrosis is the increased synthesis of matrix
components. Fibrotic livers exhibit a significant increased collagen expression as
compared to normal livers 1. To investigate whether GTX could reduce the
expression of collagen 1a1 mRNA, real-time PCR analysis on normal and fibrotic liver
slices incubated with GTX was performed. Measurement of specific primers for
collagen 1a1 mRNA showed that the Cycle time (Ct) value for the normal control was


























































































































clearly shows that the expression of collagen 1a1 is highly unregulated in fibrotic
livers. The incubation of normal and fibrotic slices with GTX showed a significant
reduction in the collagen 1a1 expression on the mRNA level. Compared to control
incubations, mRNA levels for collagen 1a1 were reduced by 32 ±11% in normal and
59 ± 11% in fibrotic liver slices by the 10 μM GTX (p<0.05, Figure 6).
Figure 6: Effect of different concentrations of GTX on the intrahepatic mRNA levels of collagen 1a1
expression in normal (open bars) and fibrotic (closed bars) liver slices. The results are expressed as
the mean ± SD (n=3 livers). * indicates p < 0.05 compared to control liver slices, # indicates p < 0.05
difference between normal and fibrotic liver slices incubated with the same concentration of GTX.
DISCUSSION
Several recent reports highlight the use of apoptosis-inducing agents as a
potential therapeutic strategy to treat liver fibrosis. Some studies show that the
compound Gliotoxin may be used for this purpose. It was shown that GTX promoted
apoptosis in HSC in vitro and reduced hepatic fibrosis through HSC apoptosis in two
rat models of liver fibrosis 4,17,18.
The aim of our studies was to examine cell-selectivity which is obviously a
crucial element of apoptosis-inducing drugs. In addition, the effect of GTX on
fibrogenesis could be examined in this manner without indirect effects on the immune
system. The drug exhibited a potent apoptotic activity in our slice-system. Both
immunohistochemical stainings and quantitative mRNA techniques elucidated that
the HSC were strongly affected by GTX. However, also Kupffer cells and liver
endothelial cells were affected by this compound. The hepatocytes were less
sensitive compared to the other cell types although negative effects of GTX on
hepatocytes were clearly visible with the PAS staining.
Induction of apoptosis in normal and fibrotic liver slices was shown with two
techniques, the active caspase-3 assay and the TUNEL staining. Both results clearly
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after GTX incubation. We also found that fibrotic slices significantly exhibited an
increased sensitivity towards GTX as compared to normal liver slices which could be
explained by the increased number of HSC in fibrotic livers and/or by an increased
sensitivity of the individual cells.
This study elicited further investigations on the effect of GTX on other resident
hepatic cells. In combination with the liver slice system, it is possible to study the
effects of GTX on each cell type using semi quantitative mRNA real-time techniques
combined with cell-specific markers 12. Real-time PCR techniques clearly
demonstrated a decrease in expression levels of many specific cell markers relative
to the housekeeping gene GAPDH. The decreases of the markers for HSC, Kupffer
cells and endothelial cells were quite significant, whereas the hepatocyte marker was
not significantly affected. Yet, the PAS staining in normal slices incubated with GTX
showed a clear decrease in the glycogen content of the hepatocytes. This reduced
glycogen content is an early response of hepatocytes to stress or injury due to an
increased glycogenolysis. These data indicate that GTX may affect hepatocytes as
well although they seem to be less sensitive towards GTX. This resistance of
hepatocytes is related to the metabolism of GTX by glutathione conjugation by these
cells. Hepatocytes metabolize GTX rapidly because these cells have high glutathione
levels. This results in a prevention of apoptosis at low GTX concentrations 19.
Our data also show that GTX significantly attenuates the collagen 1a1 mRNA
level in liver slices, which is another key process during liver fibrosis. Whether GTX
affects the level of mRNA directly or reduces the amount of cells that produce
collagen 1a1 (i.e. the HSC) remains to be established.
Recently, a growing number of publications show the ability of GTX to induce
apoptosis in HSC. Not only in the tetrachloride model, but also in the thioacetamide
model of fibrosis, significant in vivo effects of GTX were found 4,17-19. However, the
effects of GTX on Kupffer and liver endothelial cells were not studied in any of these
reports. In addition, the anti-fibrogenic effect found in all these experiments might
have been secondary to the immunosuppressive effect of GTX found in other studies
20,21
. Gliotoxin also effectively attenuated dextran sodium sulfate-induced colitis in
rats. This was associated with a systemic immunosuppressive effect of GTX. In fact,
this immunosuppressive effect appeared to seriously affect viability of the
experimental animals in this model 20. For mice, the 50% lethal dose (LD50) of GTX
was found to be 10 mg/kg. In this same study, it was demonstrated that intra-
peritoneal injections of GTX also caused apoptosis in the thymus, spleen and
mesenteric lymph nodes. This apoptotic effect was possibly a direct action of the
toxin since low concentrations of GTX were measured in these organs 21. Based on
the non-specific effect of GTX within the liver and the uptake in other organs, it
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remains to be established whether the net effect of GTX as a chronic treatment for
liver fibrosis is beneficial.
In general, the use of apoptosis-inducing drugs might be promising but full of
risks. Cell-selectivity is a crucial element in this strategy. Apoptosis of hepatocytes for
example might result in activation of the HSC by engulfment of apoptotic bodies 22.
Apoptosis of the hepatocyte during liver fibrosis should therefore be prevented, while
HSC apoptosis should be promoted 22,23. The specific delivery of the apoptotic
stimulus of GTX to the HSC can in principle be accomplished using HSC-specific
drug delivery systems. In recent years, these carrier systems have become available
and active delivery of the potent GTX might be feasible 14.
In summary, we have demonstrated the ability of GTX to induce apoptosis in
normal and fibrotic rat liver slices. We have shown that GTX also attenuates the
synthesis of collagen 1a1 in rat liver slices, probably associated with the decrease in
the number of HSC within the slice. Thus, direct effects on the key parameters of
fibrosis (HSC proliferation and collagen synthesis) are demonstrated. However, we
now also report that not only the HSC, but all resident cells in the liver are affected by
GTX. We also conclude that fibrotic liver slices appear to be significantly more
susceptible towards GTX than normal liver slices. This study shows the urge to
develop an HSC-specific apoptosis-inducing drug for the treatment of liver fibrosis.
Further research will explore the potency of this targeted approach.
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Liver fibrosis is the common response to chronic liver injury. The fibrogenic
process is consecutive to intense proliferation and accumulation of myofibroblastic
cells that synthesize scar tissue. Several lines of evidence indicate that inducing
apoptosis of myofibroblastic cells may prevent fibrogenesis. In this respect, it was
shown that Gliotoxin (GTX), a natural compound derived from a fungus, induced
apoptosis of hepatic fibrogenic cells and regression of liver fibrosis. However, this
antifibrotic approach may find limitations due to the lack of cell specificity, with a risk
of potentially adverse effects. In previous studies, we found that Mannose-6-
phosphate coupled to Human Serum Albumin (M6P-HSA) selectively accumulated in
liver fibrogenic cells. The aim of this study therefore was to couple GTX to M6P-HSA
and test its pharmacological effects in vitro and in rats with liver fibrosis. The
conjugate GTX-M6P-HSA bound specifically to HSC and reduced their viability.
Apoptosis was induced in cultures of human hepatic myofibroblasts (hMF) and in liver
slices obtained from rats with liver fibrosis. In vivo treatment with either GTX or GTX-
M6P-HSA in bile duct ligated rats revealed a significant decrease in αSMA mRNA
levels and reduced staining for this HSC-marker in fibrotic livers. In addition, GTX
affected hepatocyte functioning as reflected by a significant reduced PAS staining
and increased serum AST levels, whereas GTX-M6P-HSA did not affect these
parameters In conclusion, we developed a HSC-specific GTX construct which
showed clear biological effects in human hMF, rat HSC and in fibrotic liver slices.
Both GTX and GTX-M6P-HSA attenuated the number of activated HSC, but GTX
affected also hepatocytes. This study shows that cell-selective delivery of GTX is
feasible in fibrotic livers.
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INTRODUCTION
The hepatic stellate cell (HSC) plays a crucial role during liver fibrosis. After
hepatocyte damage, this cell-type becomes activated and starts to proliferate, during
which it transforms from a resting vitamin A-storing cell into an activated
myofibroblast-like cell. This activated HSC produces excessive amounts of
extracellular matrix compounds and inhibitors of matrix degradation, thereby strongly
affecting liver homeostasis eventually leading to cirrhosis, the end stage of fibrosis 1,2.
Animal model studies revealed that this fibrotic process is reversible. Livers
can undergo regression of fibrosis after withdrawal of the damaging stimulus 3, even
in an advanced stage of cirrhosis 4. This regression was found to be accompanied by
the disappearance of activated HSC via apoptosis. This suggests that inducing or
accelerating HSC apoptosis during fibrogenesis might attenuate or reverse the
fibrogenic process 3,5,6. However, selective apoptosis of HSC is difficult to achieve.
The fungal metabolite Gliotoxin (GTX), a member of the epipolythiodioxo-
piperazine family, has shown to induce apoptosis in human and rat HSC in vitro. In
addition, it reduced hepatic fibrosis in vivo by induction of HSC apoptosis while
leaving the hepatocytes intact in the rat CCl4 fibrosis model 7. However, other studies
showed also that GTX displayed immune-suppressive effects and promoted
apoptosis in different cell types including thymocytes, macrophages, lymphocytes,
enterocytes and several other cell lines of various origins 8-11. This indicates that GTX
can induce serious side effects outside the liver after systemic administration. Also
within the liver, GTX might induce adverse effects because we previously reported
that GTX affected not only the HSC, but also the other hepatic cell types 12.
Specific delivery of the apoptotic agent GTX to the HSC might avoid these
adverse effects. This cell-specific uptake of GTX might be accomplished by
conjugation of GTX to HSC-specific drug delivery systems. In recent years, these
carrier systems have become available. We previously reported that mannose-6-
phosphate modified human-serum-albumin (M6P-HSA) predominantly accumulated
in the HSC of fibrotic rats 13,14. Therefore, the aim of this study was to synthesize the
conjugate GTX-M6P-HSA. The binding of this construct to HSC and the






Human Serum Albumin was purchased from the Central Laboratory of Blood Transfusion
Services (Sanquin Blood Supplies, Amsterdam, The Netherlands). Gliotoxin was purchased from
Sigma (St. Louis, MO, USA). All other chemicals used were of analytical grade.
Animals
Male Wistar rats (Harlan, outbred strain, Horst, The Netherlands) were housed under standard
laboratory conditions and had free access to food and water. This study was performed in accordance
with ethical regulations imposed by Dutch legislation.
Synthesis of GTX-M6P-HSA
HSA was modified with mannose 6-phosphate groups as described previously to obtain the
drug carrier M6P28-HSA 13,14. The products of the synthesis were purified and characterized according
to standard procedures.
The subsequent conjugation of GTX to M6P-HSA is a two step reaction. First, 8 mg of 4-
dimethylaminopyridine (Fluka, Buchs, Germany) and 140 mg of succinic anhydride (Acros, Morris
Plains, NJ, USA) were dissolved in 2 ml of dry acetone. 15 mg of GTX was dissolved in 1.8 ml of the
acetone solution and reacted for 4 days. The succinic spacer will form an ester bond with the hydroxyl-
group of GTX. This ester bond can be cleaved by esterases, present within the lysosomes, releasing
the native GTX drug. The product was purified by phase separation (dichloromethane-water) and
formation of GTX-hemisuccinate was confirmed by thin layer chromatography and mass-analysis.
Subsequently, GTX-hemisuccinate was dissolved in dimethylformamid (300 μl). Isobutyl-
chlorocarbonate (30 μl, Acros,) and Tri-Butylamin (42 μl, Fluka) were added and this mixture was
stirred for 30 minutes. Meanwhile, M6P-HSA (70 mg) was dissolved in PBS (5 mg/ml). GTX-
hemisuccinate mixture was added to the M6P-HSA mixture and the reaction was stirred for 4 hours in
which GTX-hemisuccinate was coupled to the primary amine groups (İNH2) of the lysines within HSA.
The formed product (GTX-M6P-HSA) was extensively dialyzed against PBS to remove all low
molecular weight compounds. The monomeric form of GTX-M6P-HSA was separated from the dimeric
and polymeric form using sephadex preparative fast performance liquid chromatography (FPLC, GE
Healthcare, Uppsala, Sweden). The purified conjugate was dialyzed against milliQ-water to remove
salts, lyophilized and stored at -20 ˚C.
The degree of drug loading of the conjugate was determined by high performance liquid
chromatography (HPLC) after hydrolysis of the ester bond between GTX and M6P-HSA by 0.1M citric
acid / 0.2M phosphate buffer (pH 2.5). Samples were injected on a C8 reversed-phase column
(Thermo-Hypersil Keystone, Bellefonte, PA, USA) preceded by C18 Guardpak precolumn (Waters Inc,
Milford, MA, USA). The mobile phase consisted of acetonitril/H2O/PBS (35/64/1, v/v/v at a flow rate of
1.5 ml/min and detection at 254 nm.
Human hepatic myofibroblast isolation
Human hepatic myofibroblasts (hMF) were obtained by outgrowth of explants from normal
human livers 15. This procedure was performed in accordance with ethical regulations imposed by
French legislation. Cells were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with
5% Fetal Calf Serum (FCS) and 5 % Human Serum (HS) and used between the third and seventh
passage. The myofibroblastic nature of the cells was routinely evaluated by microscopy and checked
for the presence of α-Smooth Muscle Actin (α-SMA).
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Rat hepatic stellate cell isolation
Primary HSC were isolated from livers of male Wistar rats (> 500 g, Harlan) 16. The HSC were
cultured in DMEM (Invitrogen) supplemented with 10% FCS, and incubated in a 5% CO2 humidified
atmosphere at 37 °C. Cells cultured for 10 days were used for further experiments. At this time point,
all cells have the phenotype of activated HSC as assessed by routine immunohistochemical methods.
Biological effects on HSC
HSC binding assays were performed with 125I-labelled GTX-M6P-HSA 17 according to standard
methods 14. Furthermore, the effect of GTX-M6P-HSA on the viability of the HSC was assessed. HSC
(5,000 cells/96-well) were incubated for 24 hours in 200 μl medium without serum. Subsequently,
GTX, GTX-M6P-HSA or M6P-HSA was added in increasing concentrations and the cells were
incubated for another 18 hours. Alamar blue (20 μl, Serotec, Oxford, UK) was added and the cells
were incubated for an additional 24 hours. The conversion of alamar blue redox indicator by metabolic
activity of cells reflects the number of cells (i.e. net result of proliferation and apoptosis) present in
each well. The alamar blue conversion was measured using a fluorimeter 18.
Apoptosis assays on hMF
Caspase-3-like activity was assayed on cell lysates according to standard methods 19. Briefly,
after incubation of hMF (300,000 cells in 60-mm dishes) with GTX, GTX-M6P-HSA or M6P-HSA, cells
were lysed and DEVDase activity was measured in 200 μl of assay buffer, containing 50 μg of total
protein and 20 μM AC-DEVDAFC (Biomol, Tebu, France) as fluorogenic substrate. Apoptosis was also
assessed by nuclear stainig with DAPI (Roche Diagnostics, Indianapolis, IN, USA) in cultures of non-
confluent hMF incubated with either GTX, carrier or conjugate according standard methods 19.
Induction of fibrosis
Rats (220-240 g, Harlan) were subjected to bile duct ligation (BDL) 20 and used for slice
experiments, 3 weeks after BDL, or for in vivo effect studies, 10 day after BDL (BDL-10d).
Liver slices
Precision-cut liver slices were prepared from 3 week BDL fibrotic rats (n=3) according
standard techniques 21. Slices were incubated individually in 6-well plates with vehicle, GTX-M6P-HSA
or M6P-HSA. After 24 hours of incubation, the liver slices were snap-frozen in liquid N2 for the active
caspase-3 assay or frozen in isopentane (-80 °C) for TUNEL analysis.
Apoptosis assay on liver slices
Slices were homogenized in caspase lysis buffer (fluorimetric caspase assay kit, Promega,
Madison, WI, USA) with a sonicator. The total protein concentration of these homogenates was
determined according to standard procedures (BioRad Laboratories, Hercules, CA, USA). The
caspase-3 activity was measured in 25 μg total protein homogenate and incubated for 60 min at 37 °C
according to the instructions of the manufacturer (Promega).
TUNEL assay
Cryostat sections (4 μm) of the liver slices were fixed in 4% paraformaldehyde and apoptotic
cells were stained with a TUNEL staining kit according to the procedure provided by the manufacturer
(Roche Diagnostics). In addition, sections were stained with the DAPI staining solution (Roche




In vivo effect studies
To assess the effects of the compounds on the number of HSC within fibrotic livers, we treated
BDL fibrotic rats at day 6, 7, 8 and 9 after the ligation and examined the rats 24 hours later at day 10
(n=5 per group). Rats were i.v. injected with vehicle (PBS), M6P-HSA (5 mg/kg), GTX-M6P-HSA (5
mg/kg) or GTX (10 ȝg/kg, equivalent to 0.4 molecules of GTX coupled to one M6P-HSA molecule), all
dissolved in PBS.
Immunohistochemical stainings
Acetone-fixed cryostat sections (4 μm) of liver sections were stained with indirect
immunoperoxidase methods 13. The activated HSC in the livers were detected with the monoclonal
antibody against ĮSMA, (Sigma). Goat polyclonal antibodies against rat collagen type I and III (both
Southern Biotech, Birmingham, USA) were used simultaneously to stain the most important interstitial
collagens in the livers. Staining was visualized with peroxidase-conjugated rabbit anti-mouse or rabbit
anti-goat IgG (DAKO, Glostrup, Denmark) and with 3-amino-9-ethylcarbazole (AEC; Sigma). The level
of fibrosis was scored for each collagen-stained liver according to Ishak Knodell score 22,23. ĮSMA
staining was also analyzed with ImageJ software (National Institute of Health, Bethesda, Maryland,
USA). On ten digital photos per liver, the total area stained positive for ĮSMA was measured and
related to the total area analyzed at a magnification of 100X.
Real-time PCR
Total RNA was isolated from rat livers using the RNeasy kit (Qiagen, Hilden, Germany) and
the amount of RNA was measured with the NanoDrop ND1000 (Nanodrop Technologies, Wilmington,
USA). The reverse transcriptase reaction (Promega) was performed with random primers.
The transcription levels of rat collagen type 1α1 (forward, 5’-AGCCTGAGCCAGCAGATTGA-
3’, reverse, 5’-CCAGGTTGCAGCCTTGGTTA-3’) and αSMA (forward, 5’- GACACCAGGGAGTGA
TGGTT-3’, reverse, 5’- GTTAGCAAGGTCGGATGCTC-3’) were detected by quantitative real time
PCR methods with SYBR Green on a ABI 7900HT apparatus (both Applied Biosystems, Foster City,
CA, USA). Formation of single products was confirmed by analyzing the dissociation step at the end of
each PCR reaction. The data were quantified via comparative ΔΔCt calculation (GAPDH was used as
housekeeping gene), and the gene expression levels in livers from normal rats were set at baseline.
Liver function
Periodic acid Schiff (PAS) histochemistry: Paraffin imbedded sections (5 μm) of livers were
fixed in 4% formalin / methanol, incubated with periodic acid and stained with Schiff’s reagent (Merck)
12
. The PAS-stained areas were quantified using ImageJ software (National Institute of Health). On
digital photos, the total area stained positive for PAS was measured and related to the total area
analyzed per liver section at a magnification of 200X.
Blood analysis : Heparinized blood was collected by heart-puncture and plasma levels for
Alanine Aminotransferase (ALT), Asparate Aminotransferase (AST) and total bilirubin were routinely
measured (Department of Clinical Chemistry, University Medical Centre Groningen, The Netherlands).
Statistics
Results were expressed as mean ± SEM. Statistical analysis of the in vitro experiments was
performed by a two-tailed Student’s t-test. The results of the in vivo effect studies were analyzed by a
one-way ANOVA followed by the LSD post-hoc test. P values lower than 0.05 were considered
statistically significant.
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RESULTS
Characterization of the GTX-M6P-HSA conjugate
The monomeric protein fraction of the GTX-M6P-HSA conjugate was
separated from the total protein fraction by preparative size exclusion
chromatography. This monomeric fraction was used in this study. HPLC-analysis
revealed that the coupled GTX to M6P-HSA ratio was 0.4:1.
In vitro studies of GTX-M6P-HSA on rat HSC
We investigated the pharmacological effects of GTX-M6P-HSA on primary
isolated rat HSC by binding and viability studies. The binding studies showed
selective binding of 125I-labeled GTX-M6P-HSA to receptors on HSC (Figure 1A).
Binding of the conjugate to HSC was reduced by 89 ± 3 % (P<0.05) after co-
incubation with M6PHSA, which is an M6P/IGF-II receptor ligand 14.
Figure 1: Effect of GTX-M6P-HSA on rat HSC. A: Binding of
125
I-GTX-M6P-HSA to activated rat HSC.
Note that preincubation with M6P-HSA, a ligand for the M6P/IGF-II receptor, reduces binding of the
conjugate by 89 ± 3 %. B: Viability of isolated activated HSCs incubated with different concentrations
of GTX. The control cells (incubated with vehicle) are set at 100% viability, whereas control wells
without cells are set as 0% viability. C:. Viability of isolated activated HSCs incubated with different
concentrations of GTX-M6P-HSA (closed bars) and M6P-HSA (open bars) Protein concentration and




























































































As previously described 7, GTX dramatically induced apoptosis of HSC
resulting in a dose-dependent decrease in viability of cultures of activated HSC,
treated for 24 hours with GTX. A significant decline in viability was found at 0.1 μM
concentration of GTX (Figure 1B). GTX-M6P-HSA also dose-dependently decreased
the viability of HSC after incubation. This decrease was significant at a concentration
of 25 μg/ml corresponding with a drug concentration of 0.13 μM GTX. Incubation of
HSC with the carrier alone did not affect the viability of HSC at all (Figure 1C).
GTX-M6P-HSA induces apoptosis in human hepatic myofibroblasts
To asses whether GTX-M6P-HSA would also affect human cells, we
conducted an active caspase-3 assay on human hepatic myofibroblasts (hMF). Both
GTX and GTX-M6P-HSA were able to increase the level of active caspase-3
compared with the control (vehicle) incubated hMF (Figure 2A). The carrier alone
(M6P-HSA) did not induce apoptosis of hMF, even at high concentrations (500 μg/ml,
Figure 2B). Condensated nuclei were detected with DAPI staining in GTX and GTX-
M6P-HSA treated cultures, confirming the results found with the active caspase-3
assay (Figure 2B).
Figure 2: Apoptotic effects of GTX and GTX-M6P-HSA in cultures of human hMF. A: The effect of
GTX and GTX-M6P-HSA on caspase-3-activity (* indicates p < 0.05 compared to control incubations).
B: DAPI staining of the nuclei (x680). Serum deprived cells were incubated for 20 h with vehicle or in
the presence of 0.25 μM GTX, 100 μg/ml GTX-M6P-HSA or 500 μg/ml M6P-HSA.
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GTX-M6P-HSA induces apoptosis in fibrotic liver slices
Previously, we showed a GTX-induced apoptotic response in rat liver slices. In
the present study, we incubated fibrotic rat liver slices with control (PBS), GTX-M6P-
HSA or M6P-HSA and measured induction of apoptosis by assessment of the
caspase-3 activation. The maximal fold induction of caspase-3 activation was 4.2 ±
0.3 after 24 hours incubation with 500 μg/ml GTX-M6P-HSA as compared with slices
incubated with vehicle (Figure 3). Incubation of slices with M6P-HSA did not result in
a significant induction of caspase-3 activity. Previous experiments showed that
apoptosis in fibrotic slices occurred at a concentration of 1 μM GTX, which is
equimolar to the present conjugate concentration 12.
Figure 3: Induction of caspase-3 activity by GTX-M6P-HSA in fibrotic liver slices. Slices were
incubated for 24 hours with vehicle, GTX-M6P-HSA or M6P-HSA (* indicates p < 0.05 compared to
control incubations).
TUNEL staining was performed on fibrotic liver slices to visualize the induction
of apoptosis. These slices showed a strong increase in TUNEL-positive cells after
incubation with 500 μg/ml GTX-M6P-HSA. Again, incubation of slices with vehicle or
with M6P-HSA did not result in an increase in TUNEL-positive cells (Figure 4).
In vivo effects of GTX-M6P-HSA
We next progressed to in vivo studies in order to determine the ability of
targeted GTX to modulate the fibrogenic response in the BDL model. ĮSMA mRNA
levels were examined in livers of fibrotic rats following reatment with GTX, M6P-HSA,
GTX-M6P-HSA or PBS (Figure 5). Treatment of rats with GTX and GTX-M6P-HSA
resulted in a significant reduction in ĮSMA mRNA levels compared with the PBS-
treated groups (p< 0.05). The carrier M6P-HSA had no effect on the ĮSMA mRNA
expression levels. No significant differences in the mRNA expression levels of






































Figure 4: Representative microphotographs of the simultaneous detection of the nucleus (DAPI
staining) and apoptotic cells (TUNEL staining) in fibrotic liver slices after 24 hours incubation with
vehicle, GTX-M6P-HSA or M6P-HSA (both 500 μg/ml, magnification 200X).
Figure 5: Real-time PCR analysis of mRNA levels for αSMA in livers after treatment of BDL fibrotic
rats with PBS, GTX-M6P-HSA, M6P-HSA or GTX. The αSMA expression was significantly reduced
when rats were treated with GTX-M6P-HSA and GTX compared to PBS and M6P-HSA-treated rats.
As a reference, αSMA expression levels of the treated groups were compared with the expression in
healthy, non-fibrotic rats. GAPDH was used as a reference gene. Data represent the average of 5
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Liver sections of rats treated with GTX or GTX-M6P-HSA displayed a clearly
reduced immunohistochemical staining for ĮSMA compared with control treatment.
Morphometric analysis of these sections revealed a significant reduction in the
number of ĮSMA positive cells in rats treated with GTX and GTX-M6P-HSA as
compared with rats treated with M6P-HSA or PBS (ANOVA, p<0.05, Figure 6A and
6C). Liver sections were also stained for the presence of collagens and the degree of
fibrosis was scored according to Ishak-Knodell 22,23. No significant effects were seen
on the degree of fibrosis or the deposition of collagen between the different treated
groups (Table 1).
Table 1: Effects of the different treatments in fibrotic rats. The interstitial collagen deposition was
scored according Ishak-Knodell. Serum levels for ALT, AST and total bilirubin were analyzed. ALT and
AST are expressed as unit per liter (U/L), whereas total bilirubin levels are expressed as μM (n=5 rats
per group, * p < 0.05, ANOVA).
PBS GTX-M6P-HSA GTX M6P-HSA
Ishak-Knodell 3.3 ± 0.5 2.8 ± 0.4 2.8 ± 0.2 2.8 ± 0.4
Serum levels for
ALT (U/L) 90.5 ± 8.8 107.8 ± 9.7 116.8 ± 10.5 99.8 ± 9.5
AST (U/L) 200.8 ± 45.8 294.4 ± 41.0 341.0 ± 33.1* 226.6 ± 34.9
Bilirubin (μM) 201.5 ± 23.6 201.2 ± 10.4 192.6 ± 10.2 213.8 ± 9.6
To assess the effects of the different treatments on markers for other hepatic
cells within the liver, mRNA levels for Kupffer cells (fucose receptor mRNA) and
Endothelial cells (eNOS mRNA) were determined 12. In addition, sections were
stained for ED2 and RECA1 as protein markers for Kupffer cells and Endothelial cells
respectively. These experiments revealed no significant effect on Kupffer cells and
Endothelial cells in mRNA expression levels and immunohistochemical staining,
indicating that the number of Kupffer cells or sinusoidal endothelial cells were not
affected by GTX, GTX-M6P-HSA, M6P-HSA or vehicle treatment (data not shown).
PAS staining was performed to visualize the glycogen content of the liver, and
clear changes were found. Quantification of this PAS staining using ImageJ
demonstrated a significant reduction in livers of GTX-treated rats whereas the PAS
staining in all other groups were similar to control animals (Figure 6B and 6C).
Measurement of serum parameters showed that bilirubin levels were similar in
all groups, confirming that the surgical procedure led to a similar level of cholestasis
in all experimental groups. No significant difference in serum levels for ALT were
found between the different treated groups, but AST levels were higher in the GTX-
treated rats (p< 0.05, ANOVA, Table 1).
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Area positive for PBS GTX-M6P-HSA GTX M6P-HSA
Į-SMA (%) 4.3 ± 0.7 2.5 ± 0.5* 2.3 ± 0.3* 4.1 ± 0.6
PAS (%) 39.4 ± 3.7 44.0 ± 3.2 25.4 ± 6.1* 40.6 ± 2.4
Figure 6: Representative microphotographs of A: Immunohistochemical staining of HSC, detected
with a monoclonal antibody specific for αSMA. Note the decrease in αSMA staining after treatment of
rats with GTX or GTX-M6P-HSA. B: Periodic Acid Schiff (PAS) staining for glycogen content of
hepatocytes. (Magnification 100X) C: Morphometric analysis of the area positive or αSMA or PAS
staining using ImageJ software by measuring the total area stained as a percentage of the total area
per digital photo (For αSMA, *p<0.05, ANOVA, GTX-M6P-HSA and GTX compared to PBS and M6P-
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DISCUSSION
In the past few years, several reports have shown beneficial effects of GTX in
experimental models of fibrosis 7,24-26. The ability of GTX to induce apoptosis in HSC
may be a pivotal step in the resolution of fibrosis 3. However, the activities of GTX are
not specific for HSC alone 12. GTX was discovered as an antibiotic drug made by the
fungus Gliocladium fimbriatum 27. Later, it was found that GTX also suppressed the
immune system 10,28, and related to this, GTX effectively attenuated dextran sodium
sulfate-induced colitis in rats. This GTX-induced immunosuppressive effect appeared
to seriously affect viability of the experimental animals in this model 29. For mice, the
50% lethal dose (LD50) of GTX was found to be 10 mg/kg 28 and it was demonstrated
that intra-peritoneal injections of GTX also caused apoptosis in the thymus, spleen
and mesenteric lymph nodes 28. In view of the non-specific effects of GTX within the
liver 12 and the uptake in other organs, we designed a more sell-selective approach
for this apoptosis-inducing drug in fibrotic livers.
In recent years, HSC-specific drug carrier systems have been developed 13,30.
The modification of HSA with Mannose-6-phosphate groups resulted in a carrier that
accumulated in HSC by binding to the M6P-IGFII receptors found on activated HSC
13,31
. After binding of M6P-HSA to this receptor, internalization of the ligand-receptor
complex in endosomes occurred and within this cellular compartment, lysosomal
enzymes degrade the proteins 32. We now coupled GTX via an ester bond to the
protein backbone of the carrier. After internalisation, lysosomal degradation of the
protein or destruction of this bond by esterases will result in the release of native
GTX within HSC.
Binding of GTX-M6P-HSA to the target cells was studied in cell cultures and
the pharmacological effects of released GTX were examined in vitro. These studies
showed specific binding of the conjugate to HSC. In addition, a decrease in cell
viability and an increase in caspase-3 activity were found after incubation of rat HSC
or human hMF with GTX-M6P-HSA. This shows that active GTX is released from the
carrier and receptor interaction of the drug-carrier construct is intact. These
experiments also indicated that the potency of GTX and GTX-M6P-HSA in vitro was
near equal.
We previously reported on the activity of GTX in rat liver slices 12. The normal
tissue architecture and complex cell-cell interactions are preserved in these liver
slices, mimicking the in vivo situation 21. Incubation of fibrotic slices with GTX-M6P-
HSA resulted in a strong induction of apoptosis as detected by the caspase-3 assay
and by increased TUNEL staining in these slices. These results prompted us to start
the in vivo experiments.
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We injected BDL fibrotic rats on day 6, 7, 8 and 9 with PBS (vehicle), GTX,
M6P-HSA or GTX-M6P-HSA. Twenty-four hours after the last injection, the rats were
sacrificed and the presence of activated HSC was examined. Since activated HSC
express ĮSMA, we stained the livers for the presence of ĮSMA and found a
decreased ĮSMA staining in the rats that were treated with GTX or GTX-M6P-HSA
compared with M6P-HSA or vehicle treatment. Quanitative measurements of ĮSMA
mRNA levels confirmed the reduction in ĮSMA found by immunohistochemical
techniques. No effects of GTX and GTX-M6P-HSA were found on other non-
parenchymal cells, as demonstrated with ED2 and RECA1 staining and
measurement of cell-specific mRNA levels (fucose receptor and eNOS). In addition,
we examined the effect of GTX on hepatocytes by serum-analysis and PAS staining.
Hepatocytes rapidly respond to stress or injury by activation of glycogenolysis leading
to a reduced glycogen content which can be demonstrated by PAS staining 12. The
PAS staining of livers was significantly reduced in the hepatocytes after treatment
with GTX as compared with vehicle, M6P-HSA or GTX-M6P-HSA treated rats. A
small but significant effect of GTX was also noted on AST levels. AST is associated
with hepatocytes and is raised as a result of acute liver damage 33. These data
indicate that GTX not only affects the HSC, but hepatocytes as well, whereas GTX-
M6P-HSA did not display these side-effects on hepatocytes at all.
Although we found an induction of apoptosis in vitro on cells and in fibrotic liver
slices, we were not able to find a significant apoptotic response in vivo. An
explanation for this may be that apoptosis can occur very fast, ranging from minutes
to a few hours after treatment 34, which prevents its detection after 24 hours.
Moreover, it has been shown that apoptotic cells are rapidly and efficiently removed
by macrophages 35 resulting in a short half-life and a narrow window for detection of
the apoptotic bodies 36.
We were also not able to detect an effect of GTX or targeted GTX on collagen
deposition. Neither Ishak-Knodell scores nor mRNA levels for collagen were affected
by the treatment. This may be due to the very low doses of GTX that were applied in
the present study (10 μg/kg rat). Apparently, the most potent effect of GTX is on the
number of activated HSC, which fits with its action as an apoptosis inducing drug in
vitro.
In conclusion, we developed a HSC-specific gliotoxin construct which showed
clear biological effects in rat HSC and in fibrotic liver slices as well as in human hMF.
Both GTX and GTX-M6P-HSA attenuated the synthesis of ĮSMA in vivo. However,
adverse effects on liver toxicity after treatment with untargeted GTX were detected,
whereas treatment with targeted GTX did not reveal any adverse effects. This
demonstrates that a targeted approach with GTX for the treatment of liver fibrosis is
feasible.
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Exacerbation of liver fibrosis after selective
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Several cellular processes associated with fibrogenesis are controlled by
cyclo-oxygenase-2 (COX-2) activity. Because opposite effects of COX-2 products are
reported in different hepatic cell types, only a cell-selective intervention of COX-2
activity may lead to the unravelment of the role of this enzyme during fibrosis in vivo.
To study COX-2 related effects in Hepatic Stellate Cells (HSC) in rats with liver
fibrosis, we conjugated a COX-2 inhibitor, niflumic acid (NFA), to the HSC-selective
drug carrier M6P-HSA (Human Serum Albumin modified with Mannose 6-Phosphate
groups). HPLC analysis confirmed the covalent binding of NFA to M6P-HSA. To
assess whether the conjugate NFA-M6P-HSA was able to exert a COX-2 related
effect, we measured intracellular cAMP levels in human hepatic myofibroblast
cultures. NFA-M6P-HSA reduced cAMP concentrations significantly in
myofibroblasts. Subsequently, the in vivo distribution of NFA-M6P-HSA showed that
after iv injection, this conjugate accumulated predominantly in the fibrotic rat livers, in
particular in HSC. Finally, in vivo studies assessing the effects of this HSC-specific
COX-2 inhibitor on the progression of liver fibrosis revealed that administration of
NFA-M6P-HSA to bile duct ligated rats from day 3 to day 10 clearly enhanced the
fibrotic process. The hepatic collagen deposition was significantly increased in these
rats as compared to the control groups. In conclusion, coupling of NFA to M6P-HSA
yielded a pharmacological active product. The effects of the HSC-specific COX-2
inhibitor in vivo appeared to be profibrotic. This study provides insight into the role of
COX-2 in HSC during liver fibrosis in vivo and tools for a cell-specific manipulation of
this enzyme activity.
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INTRODUCTION
Prostaglandins (PG) are involved in the regulation of inflammation, cellular
proliferation, apoptosis, and wound repair. These endogenous mediators are formed
by enzymatic conversion of arachidonic acid by the enzyme cyclo-oxygenase (COX).
Two isozymes are described, COX-1 and COX-2. COX-1 is constitutively expressed
in most cell types, whereas COX-2 is mainly present in an inducable form. The
induction of COX-2 occurs in particular in inflammatory conditions, and stimuli known
to induce COX-2 are for instance LPS, IL-1, TNFĮ, PDGF and TGFȕ 1,2. COX
enzymes mediate the conversion of arachidonic acid into prostaglandin H2 (PGH2),
and subsequently various prostaglandin synthases convert PGH2 into other PG
forms. In addition, PGH2 can be converted in tromboxanes. Due to the fact that in
different cell types different PG synthases are expressed and different receptors for
the prostanoids are present, the biological effects of COX activity are cell-specific 3,4.
In the progression of liver fibrosis, induction of COX-2 activity is observed in
both Kupffer cells (KC) and Hepatic Stellate Cells (HSC) 5-8. In KC, COX-2 induction
is associated with the production of PGE2, PGD2, and thromboxane A2.
Consequently, induction of COX-2 in KC leads to increased levels of TNFĮ and lipid
peroxidation in KC, and triglyceride accumulation in hepatocytes 8-10. In HSC, COX-2
is reported to be constitutively expressed. However, this expression can be further
upregulated by for instance endothelin-1 and TNFĮ via an activation of the NFțB
pathway. Activation of COX-2 in HSC, and the formation of PGE2, was associated
with an inhibition of cellular proliferation 6,11. In addition, 15d-PGJ2 can be formed by
COX-2 in HSC, and this PG is a potent inducer of apoptosis in these cells 12.
Administration of PGE2 to rats with liver fibrosis was reported to result in a reduction
of hepatic collagen production 11,13. So, COX-2 activity plays a significant role in the
control of several, sometimes opposite, processes during fibrosis: whereas COX-2
products in one cell type (Kupffer cells) lead to profibrotic effects, COX-2 activity in
other cells of the liver (HSC) lead to antifibrotic effects. Only a cell-selective
intervention may lead to the unravelment of the role of COX-2 in a particular cell type
in vivo, and possibly to an antifibrotic therapy.
To obtain cell-selective intervention in vivo, drug targeting can be applied 14,15.
To be able to study the role of COX-2 or its products in HSC in vivo, we prepared a
HSC-specific form of a COX-2 inhibitor by coupling the drug to the HSC-selective
carrier M6P-HSA (Human Serum Albumin modified with Mannose 6-Phophate
groups) 16. Many COX-2 inhibitors are described, of which the coxibs (celecoxib,
rofecoxib, etc) are the most frequently used 17. We selected niflumic acid (NFA),
because this particular COX-2 inhibitor possesses appropriate groups (carboxylic
acid group) that allows chemical coupling to the albumin carrier. The IC50 value of
NFA for COX-2 was reported to be 20 nM, whereas the inhibition of COX-1 was less
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potent (IC50 = 2 μM)18,19. In the present series of experiments, we prepared NFA-
M6P-HSA and studied the binding and uptake of this construct in vitro and in vivo. In
vitro capability to inhibit COX-2 activity was measured by studying the effect of the
construct on intracellular cAMP levels in HSC. Furthermore, this conjugate was
administered to rats with liver fibrosis in order to study the effects of cell-selective
COX-2 inhibition in HSC in vivo on the fibrogenic process.
MATERIALS AND METHODS
Materials
Human Serum Albumin (HSA) was purchased from the Central Laboratory of the Blood
Transfusion Services (Sanquin Blood Supplies, Amsterdam, The Netherlands) and consisted of >95%
monomeric protein. The COX-2 inhibitors used in this study were niflumic acid (NFA, obtained from
ICN, Biomedicals Inc., Zoetermeer, The Netherlands) and NS398 (Biomol, Tebu, France). DMEM
(Dulbecco’s modified Eagle’s medium) and Fetal Calf Serum (FCS) were obtained from Invitrogen
(Carlsbad, CA, USA) and Biowhittaker Europe (Verviers, Belgium), respectively.
Animals
Male Wistar rats (Harlan, Horst, The Netherlands) were housed under standard laboratory
conditions with free access to lab chow and water. The study as presented was approved by the local
committee for care and use of laboratory animals and was performed according to strict governmental
and international guidelines on animal experimentation.
Rat model for liver fibrosis
Liver fibrosis was induced in rats ( 250 g) by common bile duct ligation (BDL) under
isoflurane/N2O/O2 anaesthesia 16.
Synthesis
M6P-HSA: HSA was modified with mannose 6-phosphate groups to obtain the carrier protein
M6P-HSA, as described previously 16. The ratio used to couple thiophosgene-activated M6P to HSA
was 300:1.
NFA-M6P-HSA: The carboxylic acid group of niflumic acid (NFA) (50 mg in 1 ml DMF) was
activated with 74 mg N,N-dicyclohexylcarbodiimide (DCC, Sigma, St. Louis, MO, USA) dissolved in
DMF 500 μl, and reacted for 1 hr. Then, the NFA/DCC solution was added to 30 mg M6P-HSA
(dissolved in PBS in a concentration of 2 mg/ml) and the reaction was proceeded overnight. After this,
the reaction mixture was extensively dialysed at 4oC against milliQ water to remove low molecular
weight compounds, lyophilized, and stored at –20°C.
Characterization
M6P-HSA was characterized for protein, sugar and phosphate content as described 16,20. In
the present series of experiments, we used the carrier that contained an average of 30 M6P groups
coupled per albumin.
FPLC: M6P-HSA and NFA-M6P-HSA were analyzed with an FPLC (Fast Protein Liquid
Chromatography) system (GE Healthcare, Uppsala, Sweden): the percentages of monomeric protein
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in the preparations were determined with a Sephadex200 column, and the net negative charge was
analyzed with a MonoQ column 16.
HPLC analysis was performed to establish the number of NFA drugs coupled to the protein
and also to determine the amount of free drug in the preparation. The HPLC method used to detect
NFA was based on the analysis as described by Avgerinos et al 21. Briefly, an HPLC (Waters 600
Controller 717 plus Autosampler) was equipped with a μBondapack C18 column (Waters) and a 486
Tunable Absorbance Detector (Waters). At 330 nm NFA was detectable, while other proteins (M6P-
HSA components) and solvents did not disturb the NFA signal. To elute the compounds the eluent 0.1
M NaAc:ACN pH7 (60:40) was used at a flow rate of 1 ml/min.
To determine the amount of NFA molecules coupled to the carrier, the preparations (2 mg/ml)
were dissolved in 6N HCl, incubated for 18 hrs at 110°C in order to completely hydrolyse the amide
bond between NFA and the protein (acid hydrolysis). Subsequently, the mixture was diluted in eluent
(30x), and a sample was injected on the HPLC system to determine the amount of total NFA. A
calibration curve was prepared with various concentrations of NFA. NFA treated with 6N HCl overnight
at 110°C showed the same calibration curve as a freshly prepared NFA standard curve. This indicated
that the drug was stable during the hydrolysis procedure.
In order to assess the amount of uncoupled NFA in the preparations, the compound was
freshly dissolved in milliQ in a high concentration (10 mg/ml), diluted in eluent (30x), and immediately
injected on the HPLC system.
In vitro effects.
Cell isolation and culture: Human hepatic myofibroblasts (hMF) were obtained by outgrowth of
normal liver explants as described previously 22. This procedure was performed in accordance with
ethical regulations imposed by the French legislation. The cells were routinely characterized by
positive immunostaining for Į-smooth muscle actin. Experiments were performed with the cells
between passages 3 and 8.
Cell Viability: hMF (10,000 cells/well in 96-well plates) were seeded and grown to confluency
in DMEM containing 5% human serum and 5% fetal calf serum (DMEM 5/5), and serum-starved for 48
hours in Waymouth medium. Subsequently, cells were incubated with the various compounds (NFA,
M6P-HSA, NFA-M6P-HSA) or their vehicles for 8 hours. The viability of the cells was determined after
addition of CellTiter 96 AQueous One Solution reagent (Promega, Madison, WI, USA) to each well,
and absorbance was recorded at 490 nm.
cAMP measurements. The in vitro effects of the conjugate were assessed with cAMP analysis
as described 22. Briefly, human hMF were seeded in 24-well plates and grown to confluency in DMEM
5/5. Subsequently, the cells were serum-starved for 48 hours in Waymouth medium. At t=-15 min, the
phosphodiesterase inhibitor isobutylmethylxanthine (IBMX, 1.2 mM) was added, and at t=0 min 1 μM
sphingosine 1-phosphate (S1P, Biomol) was added for 10 min to induce cAMP. Cells were incubated
for 3 hours with either NFA (1-5 μM), or the conjugated form NFA-M6P-HSA in various concentrations.
To assess the potency of NFA in cultures of HSC, the COX-2 inhibitor NS-398 (5 μM) was used as a
reference. NS-398 has been frequently applied as a COX-2 inhibitor in HSC 22-24. Control cells were
incubated with vehicle, carrier M6P-HSA, or M6P-HSA with unbound NFA in a concentration that was
maximally present in the preparations as determined with HPLC. Finally, cAMP was extracted into
ethanol for 2 hours at room temperature and the cAMP levels were measured with a commercial





In vivo localization of NFA-M6P-HSA: A bolus dose of 2 mg/kg NFA-M6P-HSA or M6P-HSA
was iv injected to rats 10 days after bile duct ligation (BDL). After 10 min, organs were removed and
frozen in isopentane (-80°C). In addition, the distribution of NFA-M6P-HSA was studied after multiple
dosing. Therefore, the protein (dose 5 mg/kg) was iv injected, under fluothane/N2O/O2 anaesthesia in
the penile vein, every day starting at day 3 after the bile duct ligation until day 10. At 10 min or at 24
hours after the last injection, various organs (liver, spleen, kidney and lungs) were removed and snap-
frozen in isopentane –80°C. Cryostat sections (4 μm) were immunohistochemically stained with
polyclonal antibodies against HSA (MP Biomedicals, Irvine, CA, USA) as described 16. Double-
immunostaining techniques were used to examine the cellular localization of NFA-M6P-HSA in the
liver 16. The HSC were identified by a combination of two mouse monoclonal primary antibodies:
desmin (MP Biomedicals) and glial fibrillary acidic protein (GFAP, Neomarkers, Fremont, CA, USA).
The Kupffer cells and endothelial cells were identified, respectively, with the antibodies ED2 and
HIS52 (both Serotec, Oxford, UK).
Binding of NFA-M6P-HSA to HSC.
The binding of the conjugates to HSC was immunohistochemically determined as described 25.
Briefly, HSC were isolated from livers of male Wistar rats (>450 g) according to standard techniques
26
. Rat livers were digested with collagenase P, DNAse (both Roche Diagnostics, Indianapolis, IN,
USA) and pronase (Merck KGaA, Darmstadt, Germany). The HSC were separated from the other
hepatic cells by density-gradient centrifugation and collected at the top of an 11% Nycodenz-solution.
Subsequently, the cells were cultured at 37°C in DMEM containing 10% fetal calf serum, 100 U/ml
penicillin, and 100 μg/ml streptomycin. These culture conditions allow HSC to attach and proliferate as
confirmed by light-microscopical evaluation. Cells cultured for 10 days after isolation displayed all
signs of activated HSC, based on morphological observations and positive staining of the cells for Į-
smooth muscle actin (Sigma) and collagen type I and III (Southern Biotechnologies Associates,
Birmingham, UK).
Activated HSC were trypsinized and seeded in 24-well-plates (30,000 cells/well), and cultured
overnight in medium at 37°C. After a pre-incubation of 15 min with 1% bovine serum albumin in
serum-free medium, 0.5 or 1 mg/ml M6P-HSA, NFA-M6P-HSA, HSA, or medium alone were incubated
with these HSC for 2 hours at 37°C, and immunohistochemically stained for the presence of HSA with
the polyclonal antibodies against HSA as described in the previous section.
In vivo effects.
Experimental setup: BDL-rats were treated with NFA-M6P-HSA (5 mg/kg; n=5), NFA (0.27
mg/kg; n=4), M6P-HSA (5 mg/kg; n=4) or PBS (n=4). These compounds were iv injected, every day
starting at day 3 till day 10 after ligation. 24 hours after the last injection the rats were sacrificed.
Heparinized blood was obtained to analyse the levels of various markers of (liver) injury and
cholestasis: aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin by
routine clinical chemistry (Department of Clinical Chemistry, University Medical Centre Groningen, The
Netherlands). The liver and spleen were weighed, and specimens of the livers were processed for
immunohistochemical (frozen in isopentane –80°C) analysis.
Immunohistochemical analysis: Cryostat sections (4 μm) of the livers were fixed in acetone
and stained with monoclonal antibodies directed against desmin/GFAP and Į-smooth muscle actin
(Sigma) to show the HSC in these livers, and with polyclonal antibodies directed against collagen type
I and III (Southern Biotechnologies Associates) to demonstrate the fibrotic extracellular matrix. The
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total area positively stained for collagen type I in the cryostat sections was quantified by Adobe
Photoshop (original magnification 20x).
RESULTS
To couple NFA to the protein carrier, the carboxylic acid group of NFA was
activated with DCC and subsequently attached to the εNH2-lysine residues in M6P-
HSA. HPLC analysis confirmed the covalent binding of the drug to the protein. After
acid hydrolysis, a procedure to destruct the chemical amide bond between drug and
albumin carrier, a peak emerged at the retention time of NFA. We assessed that the
preparation of NFA-M6P-HSA used in the present series of experiments consisted of
M6P30HSA substituted with a mean of 17 molecules of NFA (see Table 1). Acid
hydrolysis of HSA or M6P-HSA did not result in HPLC-signals with retention time of
NFA (at t=5.9 min). Furthermore, no peak was found in the chromatogram at the
retention time of NFA when high concentrations of NFA-M6P-HSA were freshly
dissolved in water, which indicated that the amount of free NFA in the preparation
was below detection limits (i.e. less than 5 μmol NFA per mg NFA-M6P-HSA).












HSA nd nd 97 2
Carrier:
M6P-HSA 30 nd 80 ± 17 16 ± 11
Conjugate:
NFA-M6P-HSA 30 17 ± 2 58 ± 2 41 ± 1
In addition, FPLC analysis was performed to characterize the products for the
presence of mono-, di- and polymers (Table 1). Coupling of M6P or NFA groups to
HSA resulted in a shift in retention time of the monomeric fraction from 34.5 min to
31.8 min indicating that the molecular weights of the carrier and conjugate were
increased as compared to albumin. The prepared albumins were predominantly in
the monomeric form, although for NFA-M6P-HSA an increased amount of polymers
were detectable. This is relevant with regard to a possible uptake in Kupffer cells 27.
In addition, FPLC-Sephadex analysis showed that low molecular weight compounds,
such as NFA with a retention time of 44 min, were not detectable in the
chromatograms of the conjugates, which confirmed our HPLC data.
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Figure 1: A: The effect of the COX-2 inhibitors NS398 and NFA on the cyclic AMP production of S1P-
stimulated hMF in vitro. B: Dose-dependent reduction in cAMP production of the myofibroblasts by
NFA. C: The effect of conjugated NFA on cAMP production. NFA-M6P-HSA significantly reduced
cAMP levels at various concentrations in contrast to control hMF that were incubated with carrier M6P-
HSA. In the latter control the carrier was mixed with uncoupled drug, in an amount that was maximally
present in the conjugates as assessed with HPLC. All experiments are performed with 1 μM
sphingosine 1-phosphate stimulated conditions ( * P<0.05).
We subsequently assessed whether NFA-M6P-HSA was able to exert a COX-
2 related effect in vitro. Since cAMP levels are under the influence of COX-2 activity
22
, intracellular cAMP measurements were performed in human hMF cultures to
confirm the effects of the drug in the free and coupled form. Uncoupled NFA strongly
reduced cAMP levels in myofibroblasts under basal and sphingosine 1-phosphate
(S1P) stimulated conditions. For comparison, NS398, a frequently used COX-2
inhibitor, was used. This drug attenuated intracellular cAMP peaks in response to
S1P in similar concentrations as NFA, i.e. 5 μM (Figure 1A). The reduction in cellular
cAMP levels by NFA was dose-dependent with an IC50 of 0.5 μM (Figure 1B). Similar
to the free drug, the albumin-conjugated NFA also caused a significant reduction in
the cAMP levels of S1P-stimulated myofibroblasts at concentrations higher than 1 μM
(Figure 1C). M6P-HSA itself did not affect cAMP levels, while M6P-HSA mixed with a
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preparations (as determined with HPLC analysis), affected the cAMP levels to some
extent, but was less effective compared to NFA-M6P-HSA. In addition, we assessed
that NFA was not cytotoxic for hMF up to concentrations of 30 μM. Also, neither the
carrier M6P-HSA nor the conjugate NFA-M6P-HSA did affect the viability of hMF.
Subsequently, we studied the homing of the conjugate NFA-M6P-HSA to
HSC. At first, we incubated cultured rat HSC with either the conjugate, the carrier,
NFA, or medium alone. Immunohistochemical analysis showed that HSC were only
positively stained for HSA, when NFA-M6P-HSA or M6P-HSA were incubated (data
not shown), indicating that the carrier is able to bind to HSC.
Subsequently, the in vivo distribution of NFA-M6P-HSA was studied in rats 10
days after bile duct ligation. Ten min after intravenous injection of the proteins, high
amounts of NFA-M6P-HSA were immunohistochemically detected in the fibrotic rat
livers, in particular in the perisinusoidal areas (Figure 2). Extrahepatic localization of
NFA-M6P-HSA was only observed in the spleen (red pulpa). However, the amount in
the spleen was much less as compared to the liver. Other organs such as the
kidneys and lungs were devoid of anti-HSA staining (Figure 2). The body distribution
of NFA-M6P-HSA corresponded with the reported distribution of the drug carrier
M6P-HSA16. 24 hours after intravenous injection, all organs, including liver, of rats
that received NFA-M6P-HSA or M6PHSA were negative after staining for the protein.
Figure 2: Organ distribution of NFA-M6P-HSA in rats with liver fibrosis (BDL 10 days) after iv injection.
The localization of conjugated NFA was determined after staining for HSA. A: Spleen, B: Lungs, C:











Within the fibrotic livers, the staining patterns of NFA-M6P-HSA corresponded
with a non-parenchymal cell distribution. Using double-immunohistochemical staining
procedures, we found a co-localization with HSC markers (desmin/GFAP), and to
some extent with the Kupffer cell marker ED2 (Figure 3). After counting the number
of double-positive cells, we estimated that 32±11% of NFA-M6P-HSA was present in
the HSC, while 23±3% was present in KC. Multiple dose injections of M6P-HSA or
NFA-M6P-HSA yielded a similar distribution pattern: a predominant uptake in hepatic
stellate cells was found with additional uptake in Kupffer cells.
Figure 3: Hepatic localization of NFA-M6P-HSA. Double staining of the livers for conjugate, with anti-
HSA antibodies (in red), and cellular markers (in blue) for HSC (desmin/GFAP; A.) and KC (ED2; B).
Figure A1 and B at magnification of 400. Figure A2 at magnification 1000.
Subsequently, we examined the effects of the targeted COX-2 inhibitor in rats
with liver fibrosis. Therefore, NFA-M6P-HSA was administered to BDL rats during 7
consecutive days, starting at day 3. We used rats in an early stage of fibrosis to study
the induction phase of the fibrotic process. Rats in all four groups (receiving NFA-
M6P-HSA, PBS, carrier or drug alone) displayed a similar increase in body weight
during treatment. Plasma bilirubin levels, which were elevated at day 10 as compared
to normal rats, were similar in all 4 groups indicating that the bile duct obstruction
was similar in all rats. Other plasma markers reflecting hepatocyte damage (AST,
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Figure 4: Representative photographs of the collagen type I staining in the parenchymal areas of the
rat livers at 10 days after bile duct ligation. The rats received iv injections of NFA-M6P-HSA, NFA,
M6P-HSA, or vehicle (PBS, control) for 7 consecutive days. Note the increased collagen fibers in the
group of rats that received the HSC-specific COX-2 inhibitors.
Figure 5: Quantification of the immunohistochemical starinings presented in Figure 4. Analysis of
collagen type I staining in the parenchymal areas revealed a significant increase in NFA-M6P-HSA
treated rats (*p< 0.05), whereas rats that received the free drug NFA or M6P-HSA alone did not























After microscopic evaluation of the liver, we found that the intrahepatic staining
for desmin, Į-smooth muscle actin, collagen type I and III in the bile duct ligated rats
were strongly enhanced as compared to normal livers. Ten days after ligation, the
rats had a fibrous expansion of the portal areas (stage 2 Knodell scoring), and a few
rats displayed portal to portal bridging (stage 3) 28,29. In rats treated with NFA-M6P-
HSA, collagen type I and III deposition was clearly enhanced compared to untreated
BDL-rats (Figure 4). In particular in the perisinusoidal areas and enhanced staining
for both collagen type I and III was seen. Quantitative analysis of this staining
revealed a significant increase in NFA-M6P-HSA treated rats (p< 0.05), whereas rats
that received the free drug NFA or M6P-HSA alone did not display such an increased
matrix deposition (Figure 5). No significant differences in intrahepatic desmin and Į-
smooth muscle actin staining were found between the different experimental groups
(data not shown).
DISCUSSION
Drug targeting strategies were used in this study to examine the effect of cell-
selective COX-2 inhibition in HSC in vivo. Therefore, a COX-2 inhibitor (NFA) was
coupled to the HSC-selective drug carrier M6P-HSA, and tested in a rat model of liver
fibrosis (BDL). We selected niflumic acid (NFA) to attenuate COX-2 activity because
this drug can be coupled to proteins and is equipotent to NS-398, a COX-2 inhibitor
that has been frequently applied as an inhibitor of COX-2 activity in HSC in vitro
22,24,30
. The data show that the newly prepared construct accumulates in HSC and the
COX-2 inhibitor is released from its carrier in a pharmacological active form within the
target cells in vitro. The effects of NFA-M6P-HSA in vivo show that inhibition of COX-
2 in HSC is associated with an exacerbation of the fibrotic process as reflected by
increased collagen deposition.
NFA was coupled to lysine residues within the albumin carrier via the
carboxylic acid group of the drug. The coupling procedure that was used (activation
of -COOH by DCC) resulted in an amide bond between the drug and the amino acid
lysine. When the drug-carrier is taken up by the target cells via receptor-mediated
endocytosis, the protein is degraded but the amide bond between lysine and drug
can not be cleaved by proteinases 31. As a consequence, intracellular degradation of
NFA-M6P-HSA will lead to the release of NFA-lysine. This modified NFA is still
endowed with COX-inhibiting effects, as assessed with cAMP studies in human
hepatic myofibroblasts (hMF). NFA-M6P-HSA attenuated c-AMP levels hMF to a
similar level as free NFA and both compounds were equipotent in vitro in this respect.
It has been reported that various non-steriodal anti-inflammatory drugs (NSAIDs)
become more selective COX-2 inhibitors when the carboxylate-group is modified 32;
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the enzyme COX-2 has a larger active site as compared to the COX-1 enzyme.
Attachment of lysine to the carboxylic groups of NFA apparently does allow binding to
the active site of COX-2 resulting in pharmacological effects of carrier-bound NFA in
our studies in vitro. Alterations of the carboxylic acid moiety in NFA however do
inhibit the effects of this drug on chloride channels 33, but this was not examined in
the present study.
A relation between COX-2 activity and various HSC activities has been shown
in several studies, but most of these studies were performed in cell cultures in vitro.
Several studies have shown that PGE2 can inhibit the proliferation of fibroblasts 34,35.
Collagen production by HSC is attenuated by PGE2 and 15d-PGJ2 36-38. Hui et al 39
showed in the human HSC cell line LX-1 and in isolated rat HSC that PGE2 inhibited
collagen gene expression in these cells. Administration of PGE2 to rats with liver
fibrosis caused a reduction in hepatic collagen production 11,13. In line with this, COX-
2 deficiency led to enhanced fibrogenesis in lungs 40. Addition of a COX-2 inhibitor to
HSC in vitro caused an increased collagen gene expression 41, an enhanced HSC
proliferation 22,24, and an enhanced Į-smooth muscle actin expression 24. All these in
vitro studies implicate that inhibition of COX-2 activity in HSC or myofibroblasts
promotes fibrogenesis.
However, several reports show antifibrotic effects of COX-2 inhibitors in vivo
42,43
. In sinusoidal endothelial cells (SEC) and KC, COX-2 inhibition leads to down-
regulation of the production of many pro-inflammatory mediators which may lead to
antifibrogenic effects of these drugs. It is not clear which cells have the highest COX-
2 activity during fibrosis. Hepatocytes express COX-2 activity 44 and they constitute
the majority of cells within the liver. KC respond to injury or stress by up-regulation of
their COX-2 activity, and in several models, including BDL-induced liver injury, KC
were shown to contribute predominantly to the total hepatic COX-2 activity 10,45,46.
Inhibition of this KC-derived COX-2 activity may lead to reduced fibrogenesis 47.
However, most COX-2 inhibitors are cleared via/taken up by hepatocytes, and
pharmacological effects of COX-2 inhibitors in this cell type should seriously be taken
into account. Attenuation of prostaglandin production in this cell type generally lead to
hepatoprotective effects, and hence antifibrogenic effects. Also, endothelial
dysfunction during liver fibrosis may be corrected by the inhibition of thromboxane A2
production 48,49, although this appears to be primarily mediated by COX-1 rather than
COX-2 50. On the whole, these studies suggest that COX-2 inhibitors within
hepatocytes, KC or SEC exert anti-fibrogenic effects.
The opposite effects of COX-2 inhibitors in HSC and myofibroblasts versus
hepatocytes, KC and SEC warrants further in vivo studies, and particular a cell-
selective delivery appears to be essential for this kind of drugs. It will provide insight
into the pathogenic role of COX-2 in different cell types and if uptake in particular
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cells types can be prevented, counterbalancing effects will be circumvented and the
effectivity of COX-2 inhibitors might be strongly enhanced.
The present study shows that such a cell-selective approach is feasible:
accumulation in the liver of targeted NFA with predominant uptake in HSC was
demonstrated. The minor uptake that was found in KC, still corrupts the targeting
efficiency, yet the relative uptake of NFA in HSC is most likely much higher that in the
untargeted situation since NFA is neither liver nor HSC-specific. Untargeted NFA is
metabolized by hepatocytes and cleared by the kidneys 51.
COX-2 inhibitors may be prescribed by practitioners for various inflammatory
diseases, including patients with chronic liver diseases. Care should be taken after
administration of these drugs in patients with liver fibrosis/cirrhosis, because of the
opposing effects in different cell types of the liver that lead to a complex situation.
In summary, we used the drug targeting approach to examine the effect of
COX-2 inhibition in HSC in vivo. Our studies show that cell-selective delivery of
pharmacologically active NFA in HSC is feasible and this leads to an enhanced
collagen deposition in livers of bile duct ligated rats. This study provides insight into
the role of COX-2 in HSC during liver fibrosis in vivo and provides also the tools for a
cell-specific manipulation of this enzyme activity. This study implicates an important
role for HSC-derived prostaglandins during fibrogenesis.
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Liver fibrosis can occur in response to different forms of injury. During fibrosis, the
hepatic stellate cell (HSC) becomes activated, proliferates and is the major producer
of collagens. Regression of fibrosis is associated with apoptosis of HSC. 15-deoxy-
Δ12,14-Prostaglandin J2 (15d-PGJ2) has been shown to induce apoptosis, to inhibit
proliferation and to reduce collagen synthesis in human myofibroblasts. The
therapeutic use of this compound is however limited due to the lack of cell and tissue
specificity and a very short half-life. However, selective delivery of 15d-PGJ2 to the
HSC may overcome this. The aim of this study, therefore, was to synthesize and
study a 15d-PGJ2-conjugate that selectively accumulates in the liver fibrogenic cells.
15d-PGJ2 was chemically coupled to M6P-HSA, which is known to accumulate in
HSC. In vitro assays with human hepatic myofibroblasts showed that this 15d-PGJ2-
M6P-HSA induced apoptosis and inhibited proliferation. The conjugate showed
binding to isolated rat HSC and selective and rapid accumulation in the liver in vivo.
After 15 minutes, 87% of the injected dose accumulated in the fibrotic liver. In vivo
treatment with 15d-PGJ2-M6P-HSA in BDL fibrotic rats revealed decreased
procollagen 1α1 mRNA levels and a reduction in desmin positive cells. In conclusion,
we developed the first cell-specific prostaglandin construct for HSC. This conjugate
rapidly and almost completely accumulated in the liver and decreased in the number
of HCS, associated with an attenuation of the synthesis of collagens within the fibrotic
liver.
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INTRODUCTION
Liver fibrosis is the common response to chronic liver injury, ultimately leading
to cirrhosis and its complications, such as portal hypertension, liver failure and
hepatocellular carcinoma. The fibrogenic process is consecutive to intense
proliferation of myofibroblastic cells, that synthesize extracellular matrix components
and inhibitors of matrix degradation 1,2.
A potential therapy to treat liver fibrosis would be to inhibit the accumulation of
fibrogenic cells (Hepatic Stellate Cells and myofibroblasts). In this respect, 15-deoxy-
Δ12,14-Prostaglandin J2 (15d-PGJ2) might represent an interesting drug. This
cyclopentanone exhibits several effects including growth arrest, induction of
apoptosis in different cell types and suppression of macrophage activation 3-5.
Recently, it was shown that this prostaglandin induced apoptosis of human hepatic
myofibroblasts (hMF) 6. Sub-apoptotic concentrations of 15d-PGJ2 strongly inhibited
the proliferation of hMF and reduced the expression of interstitial collagens in vitro 7,8.
15d-PGJ2 is a downstream metabolite of cyclooxygenase and is derived from PGD2
by dehydration 9. It was detected in vivo at sites of inflammation during its resolution
phase, suggesting that it might function as a negative feedback regulator of the
inflammatory process 10.
The therapeutic use of the lipophilic compound 15d-PGJ2 is limited by the lack
of cell and tissue specificity, resulting in a low efficacy and a high risk of potential side
effects. In general, all prostaglandins are locally acting mediators that are rapidly
metabolized by the lung 11 and cleared from the body by the kidneys resulting in a
very short half life. For example, PGE2 (dinoprostone) has a plasma half-life (t½) of
less than 1 minute and PGI2 (epoprostenol) has a t½ of 2-3 minutes 12,13. Also, the
high protein binding of prostaglandins in serum 14 prevents compounds such as 15d-
PGJ2 to effectively reach the target cells within the liver after systemic administration.
Therefore, selective delivery of 15d-PGJ2 to HSC can be a promising strategy
to get the active drug at the desired site. In recent years, carrier systems that allow
selective delivery of drugs to HSC have become available. For instance, mannose-6-
phosphate modified human-serum-albumin (M6P-HSA), which binds to the Insulin-
like Growth Factor II / Mannose-6-Phosphate receptor (IGF-II/M6P), has been shown
to accumulate rapidly in the HSC of fibrotic rats 15,16.
The aim of this study therefore was to synthesize and test a 15d-PGJ2-M6P-
HSA conjugate that selectively affects the activated fibrogenic cells within the liver.






Human Serum Albumin (HSA) was purchased from the central laboratory of the blood
transfusion services (Sanquin Blood Supplies, Amsterdam, The Netherlands). 15-deoxy-ǻ12,14-
Prostaglandin J2 (15d-PGJ2) was purchased from ITK Diagnostics (Uithoorn, The Netherlands). All
other chemicals used were of analytical grade.
Animals
Male Wistar rats (Harlan, outbred strain, Horst, The Netherlands) were housed under standard
laboratory conditions and had free access to food and water. This study was performed in accordance
with ethical regulations imposed by Dutch legislation.
Synthesis
HSA was modified with mannose 6-phosphate (M6P) groups and the products were purified
and characterized according to standard procedures 15,16.
Coupling of 15d-PGJ2 to M6P-HSA: The carboxylic acid group of 15d-PGJ2 (10 mg dissolved
in 150 μl dimethyl formamid) was activated with 11.7 mg N,N-dicyclohexylcarbodiimide (DCC, Sigma,
St. Louis, MO, USA) dissolved in 80 μl dimethyl formamid and stirred for 1 hour at room temperature.
Activated 15d-PGJ2 was subsequently added to 20 mg M6P-HSA (dissolved in PBS, 4 mg/ml) and
stirred for 16 hours. This mixture was extensively dialyzed against milliQ water at 4°C to remove all
low molecular weight compounds (including excess 15d-PGJ2) and the conjugate was lyophilized and
stored at -20°C.
The amount of 15d-PGJ2 coupled to the carrier was estimated by 15d-PGJ2 correlate-EIA kit
(Assay Designs, Ann Arbor, Michigan, USA). In addition, high performance liquid chromatography
(HPLC) methods were used to asses the amount of released 15d-PGJ2 after hydrolysis of the bond
between and M6P-HSA by ascorbic acid (pH 2.5, overnight at 80˚C). Samples were injected on a C18
Chromolith SpeedROD column (Merck KGaA, Darmstadt, Germany; Flow 1 ml/min,
Acetonitril/H2O/triflouroacetic acid: 50/50/0.1, detection 254 nm).
Human hepatic myofibroblast isolation
Human hepatic myofibroblasts (hMF) were obtained by outgrowth of explants of normal
human livers 17. This procedure was performed in accordance with ethical regulations imposed by
French legislation. Cells were cultured in DMEM (Invitrogen, Carlsbad, CA, USA), supplemented with
5% Fetal Calf Serum (FCS) and 5% Human Serum and used between the third and seventh passage.
The myofibroblastic nature of the cells was routinely evaluated by microscopy and checked for the
presence of α-Smooth Muscle Actin (α-SMA) by immunohistochemistry.
Rat hepatic stellate cell isolation
Primary HSC were isolated from livers of male Wistar rats (> 500 g, Harlan) 18,19. The HSC
were cultured in DMEM (Invitrogen) supplemented with 10% FCS, and incubated in a 5% CO2
humidified atmosphere at 37 °C. Cells cultured for 10 days were used for further experiments. At this
time point, all cells have the phenotype of activated HSC as assessed by microscopy and presence of
α-SMA.
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Experimental design: in vitro studies
The biological activity of 15d-PGJ2 and 15d-PGJ2 coupled to M6P-HSA was assessed in hMFs
by measuring proliferation and induction of apoptosis. Since in vivo experiments are performed in rats,
biological effects and receptor binding of the construct were also analyzed in cultured rat HSC.
Apoptosis assays on hMF
Caspase-3-like activity was assayed on cell lysates according to standard methods 3. Briefly,
after incubation of hMF (300,000 cells in 60-mm dishes) with 15d-PGJ2, carrier or conjugate, cells
were lysed and DEVDase activity was measured in 200 μl of assay buffer, containing 50 μg of total
protein and 20 μM AC-DEVDAFC (Biomol, Tebu, France) as fluorogenic substrate.
Nuclear morphology was measured with DAPI (Roche Diagnostics, Indianapolis, IN, USA)
staining in cultures of non-confluent hMF incubated with 15d-PGJ2, carrier or conjugate according
standard methods 3.
Proliferation assay on hMF
hMFs (10,000 cells/96-well) were allowed to attach overnight, serum-starved for 72 h and
preincubated for 1 hour with the indicated compounds. Subsequently, human serum (5%) was added
and 6 hours later, 3H-thymidine (0.5 μCi/well) was added and the cells were cultured for another 28
hours. Cells were washed and collected and radioactivity was measured with a ȕ-counter.
Biological effects on HSC.
Protein binding assays in cultures of HSC were performed with 125I-labelled 15d-PGJ2-M6P-
HSA 20 as described 16. Furthermore, viability of the HSC was assessed. HSC (5,000/96-well) were
incubated for 24 hours in 200 μl medium with or without 10% FCS. Subsequently, 15d-PGJ2, 15d-
PGJ2-M6P-HSA or M6P-HSA was added in increasing concentrations and the cells were incubated for
another 18 hours. Alamar blue (20 μl, Serotec, Oxford, UK) was added and the cells were incubated
for an additional 24 hours. The conversion of alamar blue redox indicator by metabolic activity of cells
reflects the number of cells (i.e. net result of proliferation and apoptosis) present in each well. The
alamar blue conversion was measured using a fluorimeter 21.
Induction of fibrosis in vivo
To induce liver fibrosis, rats (220-240 g, Harlan) were subjected to bile duct ligation (BDL) 22.
Ten days after ligation, (BDL-10d), rats were used for further experiments. At this point, liver fibrosis is
evident but not excessive yet, while the IGF-II/M6P-receptor is upregulated 23.
Organ distribution
Organ distribution experiments were performed in BDL-10d rats. Animals were injected i.v.
with a tracer dose of 125I-15d-PGJ2-M6P-HSA and 125I-HSA (1000,000 cpm per rat). Fifteen minutes
after injection, the animals were sacrificed by heart puncture and organs were collected. Radioactivity
in each organ was measured with a γ-counter and corrected for blood-derived radioactivity (n=3 per
group).
γ-camera imaging
HSA and 15d-PGJ2-M6P-HSA were radiolabeled with 123Iodine 20. Immediately after the i.v.
injection of 5 MBq in the penile vein of BDL-10d rats, the distribution of the radiolabel was dynamically
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recorded using a γ-camera from 0 to 20 minutes with a frame rate of one scan per 30 seconds (n=3
per group).
In vivo effect study
To assess the effects of the compounds on the progression of liver fibrosis, we treated BDL-
10d rats and examined these rats 24 hours later at day 11. Rats were i.v. injected with vehicle (PBS)
or with M6P-HSA, 15d-PGJ2-M6P-HSA (both 10 mg/kg) or 15d-PGJ2 (400 ȝg/kg, equivalent to ten
molecules of 15d-PGJ2 coupled to one M6P-HSA molecule), all dissolved in PBS. After 24 hours, rats
(n = 12 per group) were sacrificed and organs and blood were harvested and stored until further
examination.
Immunohistochemical stainings
Acetone-fixed cryostat sections (4 μm) of liver slices were stained using indirect
immunoperoxidase methods with peroxidase-conjugated secondary antibodies (DAKO, Glostrup,
Denmark) 15. HSC were detected with monoclonal antibodies against αSMA and desmin (both Sigma).
Goat polyclonal antibodies against rat collagen type I and III (both Southern Biotech, Birmingham,
USA) were used to stain collagen type I and III simultaneously in the livers. All stainings were analyzed
with ImageJ software (National Institute of Health, Bethesda, Maryland, USA). On ten digital photos
per liver (magnification of 100X), the total area stained positive for αSMA, desmin and collagen was
measured and related to the total area analyzed.
Real-time PCR
Total RNA was isolated from rat livers using the RNeasy kit (Qiagen GmbH, Hilden,
Germany) and the amount of RNA was measured with the NanoDrop ND1000 (Nanodrop
Technologies, Wilmington, USA). The reverse transcriptase reaction (Promega, Madison, WI, USA)
was performed with random primers. The transcription levels of rat collagen type 1α1 (forward, 5’-
AGCCTGAGCCAGCAGATTGA-3’, reverse, 5’-CCAGGTTGCAGCCTTGGTTA-3’), desmin (forward,
5’- AGGAACAGCAGGTCCA GGTA-3’, reverse, 5’- AGAGCATCAATCTCGCAGGT-3’) and αSMA
(forward, 5’- GACACCAGGGAGT GATGGTT-3’, reverse, 5’- GTTAGCAAGGTCGGATGCTC-3’) were
detected by quantitative real time PCR methods with SYBR Green on a ABI 7900HT apparatus (both
Applied Biosystems, Foster City, CA, USA). Formation of single products was confirmed by analyzing
the dissociation step at the end of each PCR reaction. The data were quantified via comparative ΔΔCt
calculation (GAPDH as housekeeping), and the levels of gene expression in livers from normal rats
were chosen as baseline.
Statistics
Results are expressed as mean ± SEM. The statistical analysis of the in vitro experiments
were performed by a two-tailed Student’s t-test, the results of the in vivo effect studies were tested by
a one-way ANOVA followed by the LSD post-hoc test. P values lower than 0.05 were considered
statistically significant.
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RESULTS
Characteristics of the conjugate 15d-PGJ2-M6P-HSA
HSA was modified with activated aminophenyl-6-phospho-Į-D
mannopyranoside to obtain M6P33-HSA 15,16. The monomeric form of this product
was separated from the dimeric and polymeric forms using preparative FPLC
sephadex separation methods. Subsequently, 15d-PGJ2 was covalently coupled to
M6P-HSA to obtain the conjugate 15d-PGJ2-M6P-HSA. The amount of 15d-PGJ2
molecules coupled to each M6P-HSA protein was estimated to be 10:1 as assessed
by HPLC and ELISA methods.
Figure 1: Apoptotic effects of 15d-PGJ2 and 15d-PGJ2-M6P-HSA in cultures of human hMF. A: 15d-
PGJ2 and 15d-PGJ2-M6P-HSA induce caspase-3-activity in hMF in a concentration dependent
manner. The estimated concentration of 15d-PGJ2 coupled to M6P-HSA is depicted as well as the
protein concentration of 15d-PGJ2-M6P-HSA. The results are expressed as the mean ± SEM (n=3, * =
p < 0.05). B: DAPI staining of the nuclei of hMF treated with 15d-PGJ2, 15d-PGJ2-M6P-HSA, M6P-
HSA or vehicle. Note the condensated nuclei in the 15d-PGJ2 and 15d-PGJ2-M6P-HSA treated hMF
(magnification 680X).
In vitro activity of 15d-PGJ2-M6P-HSA on hMF
Previously, we showed that 15d-PGJ2 induced apoptosis of human hepatic
myofibroblasts 3. Incubation of hMF with 15d-PGJ2-M6P-HSA also induced apoptosis
in a concentration dependent manner. The highest concentration tested (50 μg/ml,
corresponding with 6.4 μM 15d-PGJ2) resulted in a strong induction of caspase 3














































induce apoptosis of hMF, even at high concentrations (250 μg/ml, Figure 1A). DAPI
staining of the nucleus confirmed the results found with the active caspase-3 assay
(Figure 1B).
15d-PGJ2 is also known to inhibit proliferation of hMF 7. In the present study,
the incorporation of 3H-thymidine in hMF was significantly inhibited at a concentration
of 2 μM 15d-PGJ2 compared with control cultured hMF that were incubated with
vehicle alone (Figure 2). Incubation of hMF with 15d-PGJ2-M6P-HSA also resulted in
inhibition of proliferation. 3H-Thymidine incorporation was significantly inhibited at a
concentration when apoptosis was not detected yet (10 μg/ml, corresponding to 1.3
μM 15d-PGJ2). A higher concentration of the conjugate resulted in a negative
proliferation compared with control incubations, which is in agreement with the data
presented in Figure 1A, showing induction of apoptosis at 25 μg/ml. Incubation of
hMF with M6P-HSA alone had no significant effects on the proliferation compared
with control incubations (Figure 2).
Figure 2: Effects of 15d-PGJ2, 15d-PGJ2-M6P-HSA or M6P-HSA on the proliferation of hMF as
assessed by 3H-thymidine incorporation. Note that complete inhibition of proliferation can be achieved.
The results are expressed as the mean ± SEM (n=3, * = p < 0.05).
In vitro activity of 15d-PGJ2-M6P-HSA on HSC
To test whether 15d-PGJ2-M6P-HSA selectively binds to receptors on HSC,
we performed binding studies on culture-activated HSC with 125I-labeled 15d-PGJ2-
M6P-HSA. In Figure 3 it can be seen that binding to HSC was significantly reduced
by 81 ± 5% (P<0.05) after co-incubation with M6PHSA, which is an M6P/IGF-II
receptor ligand. In contrast, preincubation with HSA only mildly affected the binding
of 125I-15d-PGJ2-M6P-HSA to the HSC.
We also investigated the effects of 15d-PGJ2 and 15d-PGJ2-M6P-HSA on the
viability in cultures of rat HSC and the influence of serum on this since albumin is
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grown without FCS caused a significant and dose-dependent drop in viability of HSC
(84 ± 17% reduction at 20 μM 15d-PGJ2). In contrast, the same experiment in the
presence of 10% FCS showed that serum abolished the effect of 15d-PGJ2 on HSC
(Figure 4A). Subsequently, we examined the effect of 15d-PGJ2-M6P-HSA on HSC.
Without FSC, a dose-dependent reduction in viability of HSC was measured starting
at a concentration of 25 μg/ml 15d-PGJ2-M6P-HSA, corresponding with 3.2 μM 15d-
PGJ2. In the presence of FCS, 15d-PGJ2-M6P-HSA was still able to reduce the cell
number, although the dose-response curve was shifted to the right (Figure 4B, 68 ±
11% inhibition at 250 μg/ml). M6P-HSA alone showed no effect at all on the cell
number, either with or without FCS (Figure 4B).
Figure. 3: Binding of 125I-15d-PGJ2-M6P-HSA to activated HSC alone or with co-incubation with an
excess of M6P-HSA or HSA (both 1 mg/ml). Note that M6P-HSA, a ligand for the IGF-II/M6P receptor
strongly reduces cellular binding of the conjugate in contrast to HSA. The results are expressed as the
mean ± SEM (n=3, * = p < 0.05).
Figure 4: Viability of isolated activated rat HSC incubated with different concentrations of A: 15d-
PGJ2, B: 15d-PGJ2-M6P-HSA. The experiments are performed under serum starvation (closed bars)
and in the presence of 10% FCS (open bars). M6P-HSA showed no effect on the viability of HSC. The
control cells (incubated with vehicle) are set at 100% viability, whereas control wells without cells are




















































































































In vivo accumulation of 15d-PGJ2-M6P-HSA in the fibrotic liver
With a γ-camera, the biodistribution of 123I-HSA was compared with 123I-15d-
PGJ2-M6P-HSA in BDL-10d rats. The γ-camera allows visualization of the distribution
profile and assessment of the distribution of the construct in time. Figure 5A shows
the distribution of 123I-HSA in which radioactivity was seen in well-perfused organs
like kidneys and in the heart/lung area throughout the observation period, reflecting
the blood circulation. In contrast, experiments with 123I-15d-PGJ2-M6P-HSA showed
that within the first minute after injection already high levels of the conjugate were
localized in the liver area. These levels were higher than the 123I-HSA levels and
remained in the liver area until the end of the experiment (Figure 5B). From these
data we choose 15 min after i.v. injection as a relevant time point to quantify the
organ distribution of 15d-PGJ2-M6P-HSA.
Figure 5: Ȗ-Camera analysis of 123I-HSA and 123I-15d-PGJ2-M6P-HSA A: Whole body scan taken at
the end of the 20 minute test period of the distribution of 123I-HSA (left) and 123I-15d-PGJ2-M6P-HSA
(right) in BDL-10d rats after iv injection. The intensity of radioactivity ranges from black (low intensity)
to white (high intensity). B: The dynamic curve of 123I-HSA (square) and 123I-15d-PGJ2-M6P-HSA
(triangle) uptake in the liver area in the first 20 minutes after i.v. injection. L = liver, B = brain, H =
heart, K = kidney and I = injection site (n=3 per group).
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Organ distribution revealed that fifteen minutes after i.v. administration, 125I-
15d-PGJ2-M6P-HSA accumulated significantly in the livers of BDL-10d rats (86 ±
7%), leaving very little conjugate in the blood (3.3 ± 0.2%). Less than 3% of the
injected dose was taken up in other major organs and tissues including kidney, heart,
lung and spleen (Figure 6). In contrast, organ distribution studies of 125I-HSA
revealed that 57 ± 9% of the injected dose was still in the blood 15 minutes after
injection (Figure 6). In conclusion, these pharmacokinetic studies show a rapid and
almost complete targeting of the conjugate to the fibrotic liver.
Figure 6: Quantitative analysis of in vivo distribution of 125I-labeled proteins, 15 minutes after i.v.
injection in fibrotic rats (BDL-10d). Data show that 15d-PGJ2-M6P-HSA accumulated in the fibrotic
liver, whereas HSA remained in the blood (n=3 per group).
In vivo effects of 15d-PGJ2-M6P-HSA.
The pronounced effects of 15d-PGJ2 and 15d-PGJ2-M6P-HSA on HSC and
hMF and the rapid accumulation of the targeted construct in fibrotic livers prompted
us to treat fibrotic rats for 24h. We examined the effects of treatment on desmin, Į-
SMA and interstitial collagens in these rat livers, 10 days after BDL, by
immunohistochemical staining and mRNA expression levels.
Morphometric analysis of the livers stained for desmin showed a significant
reduction in livers of the rats treated with 15d-PGJ2 (39% reduction) and 15d-PGJ2-
M6P-HSA (35% reduction) compared with the PBS-treated rats (p<0.05). Treatment
of rats with the carrier alone did not result in a difference compared with the PBS-
treated rats. Single-dose treatment had also no effect on the amount of Į-SMA and
collagen type I and III in these livers (Figure 7).
Figure 8 shows the effect of treatment on procollagen 1Į1 mRNA expression.
The results are expressed as the fold induction over the expression level of
procollagen1Į1 found in normal, non-fibrotic rat livers. Ten days after induction of
fibrosis, a 33-fold increased collagen expression was found within the livers of the




















PBS-treated rats. Treatment of rats with 15d-PGJ2-M6P-HSA resulted in a significant
reduction in expression of procollagen1Į1 mRNA levels compared with the PBS-
treated groups (54% reduction). Rats treated with 15d-PGJ2 and carrier alone
showed a decline in procollagen 1Į1 mRNA expression levels compared to the PBS-
treated group but this was not significant. Treatment had also no significant effect on
the mRNA expression levels of Į-SMA and desmin found within these livers (Fig 8).
Figure 7: Results of the morphometric analysis of liver sections of the BDL-10d rats treated with
different compounds stained for desmin, ĮSMA and collagen type I and III. Hepatic desmin staining
showed a significant decrease in the desmin positive area for rats treated with 15d-PGJ2-M6P-HSA or
15d-PGJ2 compared to the PBS and M6P-HSA treated groups. Treatment did not affect the ĮSMA and
collagen type I and III staining 24 hours after a single injection (n=12 animals per group ± SEM, * p <
0.05. ANOVA).
Figure 8: Quantitative real-time PCR analysis of intrahepatic mRNA levels for desmin, ĮSMA and
procollagen 1α1 after treatment of BDL-10d rats with 15d-PGJ2, 15d-PGJ2-M6P-HSA, M6P-HSA alone
or PBS. The procollagen 1α1 expression was significantly reduced when rats were treated with 15d-
PGJ2-M6P-HSA compared to PBS-treated rats. The mRNA expression level of desmin and ĮSMA
were not significantly affected by the treatment. The mRNA expression was related to the mRNA
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DISCUSSION
Over the past few years, several reports have been published suggesting that
15d-PGJ2 is an endogenous mediator during inflammation and has antifibrotic
capacities 3-7. Its actions include an attenuation of collagen synthesis, inhibition of
proliferation and induction of apoptosis in HSC. 15d-PGJ2 is, like all prostaglandins, a
lipophilic compound that is produced locally at the site of inflammation. In general,
systemic circulation of prostaglandins results in a rapid metabolization 11 excretion 12
and plasma protein binding 14, so they will only act locally. If 15d-PGJ2 would be used
as a therapy for liver fibrosis, high systemic concentrations must be administered to
obtain sufficient effects within the liver. As a result, various adverse reactions can be
anticipated when the distribution of this apoptosis-inducing agent is not restricted to
the target area.
Targeting of prostaglandins to the desired site of action may solve these
problems. In the past, prostacycline and prostaglandin E1 have been encapsulated in
liposomes to avoid their side effects and prolong their circulation time 24. These
liposome-prostaglandin showed accumulation in the vascular lesion of hypersensitive
rats 25. With this passive targeting approach, similar to pegylation of molecules, a
prolonged circulation time leads to increased uptake in the target area. For targeting
to HSC in fibrotic livers, this passive approach is not an option since passive hepatic
uptake will occur most likely by hepatocytes and kupffer cells and not by HSC.
Therefore, we designed a construct that actively targets the HSC by coupling 15d-
PGJ2 to a HSC-specific drug carrier. The M6P-HSA carrier binds specific to the IGF-
II/M6P-receptor found on activated HSC 15,26. The free primary amine group (NH2) of
lysine groups in HSA allows coupling to the carboxylic group (COOH) of
prostaglandins. In principal, every prostaglandin can be coupled via this reaction.
After binding of M6P-containing ligands to the IGF-II/M6P-receptor, internalization of
the ligand-receptor complex in endosomes occurs 16. In these endosomes, lysosomal
enzymes degrade the M6P-containing ligands 27. For 15d-PGJ2-M6P-HSA, this
means a rapid internalisation and lysosomal breakdown of the conjugate resulting in
the release of the prostaglandin intracellularly, probably coupled to an amino-acid
since peptidases can not break down this non-peptide amide bond.
Despite this, the conjugate appeared to be biologically active. The conjugate
induced apoptosis and inhibited proliferation of human and rat fibrogenic cells.
Furthermore, the addition of serum did not abolish the effects of the conjugate,
whereas serum completely blocked the effect of native 15d-PGJ2, possibly by binding
to the proteins in serum 14. This illustrates that the pharmacology and pharmaco-
kinetics of 15d-PGJ2-M6P-HSA is completely different compared with native 15d-
PGJ2. Assuming 10 molecules of 15d-PGJ2 coupled to one M6P-HSA, the activity of
the targeted compound in vitro was similar compared with the native 15d-PGJ2.
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Coupling of 15d-PGJ2 to M6P-HSA did not affect the selective binding of the
drug carrier to its target receptor on HSC in vitro. Furthermore, in vivo Ȗ-camera and
distribution studies with radiolabeled 15d-PGJ2-M6P-HSA showed a rapid and almost
complete accumulation in the liver of BDL-10d rats, whereas HSA remained in the
blood with almost no liver accumulation. These studies indicate that selective delivery
of 15d-PGJ2 to the fibrotic liver has been accomplished.
The in vivo effect of the conjugate was subsequently tested in 10d-BDL rats.
After 10 days, liver fibrosis is evident but not excessive yet, while the IGF-II/M6P-
receptor is already upregulated in these livers 23. Twenty-four hours after a single
injection, morphometric analysis of collagen-stained tissue showed no effects on the
deposition of interstitial collagens in livers. Procollagen1Į1 mRNA, however, showed
a significant reduction (54%) in expression in animals treated with 15d-PGJ2-M6P-
HSA. This indicates that an initial step in the resolution of liver fibrosis, the reduction
of collagen expression, has occurred within 24 hours after injection.
Morphometric analysis of the desmin stainings revealed a significant reduction
of desmin-positive cells after treatment with 15d-PGJ2 and 15d-PGJ2-M6P-HSA.
Untargeted 15d-PGJ2 also caused an effect on the HSC, which was rather
unexpected since the presence of serum resulted in a total blockade of 15d-PGJ2
activity in vitro. Some reports, however, have also reported effects of 15d-PGJ2 in
vivo after IV administration 4,28,29. Therapeutic dosages of 15d-PGJ2 resulted in an
attenuation of acute and chronic inflammation. Also anti-pyretic effects were reported
with untargeted 15d-PGJ2 in animal models.
Yet, 15d-PGJ2-MP-HSA displayed a significant effect on procollagen 1α1
mRNA expression levels, whereas 15d-PGJ2 did not. Systemic administration of
untargeted 15d-PGJ2 most likely results in relatively high peak concentrations, after
which the concentration quickly drops by removal of the lipophilic compound. This
might be just sufficient to affect the desmin-positive cells, but the transient effect on
mRNA levels is gone after 24 hours. The conjugate, however, is slowly degraded in
the lysosomes, resulting in sustained release of 15d-PGJ2 from its carrier. The
receptor-mediated endocytosis and the lysosomal degradation are rate-limiting steps
which probably results in prolonged effects effect on procollagen 1α1 mRNA
expression levels that are still detectable 24 hours after injection.
In summary, we developed the first HSC-specific prostaglandin construct. This
conjugate showed clear biological effects in rat HSC as well as in hMF in vitro and a
rapid and almost complete accumulation was found in the fibrotic rat liver. The
conjugate attenuated the synthesis of collagen 1 in vivo in fibrotic rats after a single
injection and decreased the number of desmin-positive cells within the fibrotic liver.
Thus, direct effects on key parameters of fibrosis are demonstrated with this targeted
15d-PGJ2 approach.
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Cell-selective delivery of antifibrotic drugs may be an effective strategy to treat
liver fibrosis. The hepatic stellate cell (HSC) is the main target cell for such therapies,
and new HSC-selective carrier systems have become available in recent years. The
aim of this study was to examine the selective targeting of the apoptosis-inducing
drug 15d-PGJ2, using two different HSC-carriers; Mannose-6-phosphase human
serum albumin (M6P-HSA) and pPB-HSA, recognizing either insulin-like growth
factor II/ M6P (IGF-II/M6P) or Platelet Derived Growth Factor (PDGF) receptors
respectively. After coupling, both 15d-PGJ2-conjugates remained pharmacologically
active and studies showed specific binding to HSC in vitro. However, a selective
scavenger receptor antagonist reduced the binding of 15d-PGJ2-M6P-HSA to HSC.
This effect was not detected with 15d-PGJ2-pPB-HSA. Both conjugates rapidly and
massively accumulated in fibrotic livers in vivo. Intrahepatic analysis revealed that
15d-PGJ2-M6P-HSA was mainly taken up by HSC, and to a less extend by Kupffer
cells. 15d-PGJ2-pPB-HSA was also predominantly taken up by HSC, but some
uptake in all other resident hepatic cell-types was found. Assessment of target
receptors in human cirrhotic livers revealed that IGF-II/M6P-receptor expression was
enhanced in fibrogenic cells. PDGF-ȕ-receptor expression also massively increased
on fibrogenic cells within fibrotic livers. In conclusion, these studies show that 15d-
PGJ2 coupled to HSC-selective drug carriers is specifically taken up in vitro and in
vivo by the designated target cells and is highly effective in vitro within these cells.
Both carriers differ with respect to receptor specificity in vitro, leading to differences in
intrahepatic distribution during fibrosis. Nevertheless, both carriers can be applied to




Liver fibrosis may occur as a response to chronic liver injury and may lead to
cirrhosis. The Hepatic Stellate Cells (HSC) plays a pivotal role in this fibrogenic
process. This cell starts to proliferate and accumulate within the injured liver. During
this activation process, increased amounts of extra cellular matrix compounds and
inhibitors of matrix degradation are produced by these HSC, thereby strongly
affecting the liver architecture and eventually liver functioning 1,2.
Up till now, no pharmaceutical intervention is available to treat this fibrotic
disease. The application of antifibrotic drugs has not been successful, partly because
these drugs do not accumulate in the target cell in the diseased liver or cause side
effects elsewhere in the body. A potential antifibrotic therapy may therefore apply a
drug-targeting approach to alter the pharmacokinetics of the drug. This leads to
increased accumulation of the drug at the desired site, while it reduces the adverse
effects after systemic administration of the drug.
In recent years, three different HSC-selective carrier systems have become
available 3-5. One system uses the sugar Mannose-6-Phosphate which is coupled to
the protein Human Serum Albumin (HSA) to form M6P-HSA. This carrier binds
specifically to the Insulin Like Growth Factor II / Mannose-6-Phosphate receptor (IGF-
II/M6P) receptors present on HSC 6. The expression of these IGF-II/M6P receptors
increases as a result of HSC activation during liver fibrosis enabling rapid
accumulation of M6P-HSA in the HSC of fibrotic rats 3,6,7. However, some studies
suggested uptake of this carrier by other hepatic cells, probably via their scavenger
receptors 3,8.
The other two HSC delivery systems contain small cyclic peptides that mimic
the binding site of Platelet Derived Growth Factor BB to its PDGF-ȕ receptor or the
collagen type VI receptor. These peptides are chemically coupled to the protein HSA.
In particular the carrier homing to the PDGF-ȕ receptor is thought to be very relevant
since PDGF BB is the major cytokine involved in the proliferation of HSC during the
fibrotic process. As a result, the PDGF-ȕ receptor is highly upregulated on activated
HSC 9,10. The formed pPB-HSA carrier protein preferentially homed to the HSC of
fibrotic rat, although accumulation in hepatocytes has been reported 5.
A candidate drug to target specifically to activated HSC should inhibit its
proliferation and reduce its collagen synthesis. In this respect, 15-deoxy-Δ12,14-
Prostaglandin J2 (15d-PGJ2) could be an interesting drug. Recently, it was shown that
this prostaglandin, mediated by cyclooxygenase 2 (COX-2) activity, strongly induced
apoptosis of human hepatic myofibroblasts (hMF) 11. Sub-apoptotic concentrations of
15d-PGJ2 strongly inhibited the expression of interstitial collagens in human hMF as
well as its proliferation in vitro 12,13. 15d-PGJ2 was also found in vivo at sites of
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inflammation during the resolution phase of the disease, suggesting that it might
function as a negative feedback regulator of the inflammatory process 14.
However, the pharmacokinetic properties of prostaglandins including 15d-
PGJ2 limit their therapeutic use. Prostaglandins are locally acting mediators that are
rapidly metabolized by the lung 15 or in plasma 16 and cleared from the body via renal
excretion, resulting in a very short half life 17. For example, PGE2 (dinoprostone) has
a plasma half-life (t½) of less than 1 minute and PGI2 (epoprostenol) has a t½ of 2-3
minutes 18. Also the high protein binding of prostaglandins in serum 19 might prevent
15d-PGJ2 to effectively reach the essential cells within the liver after systemic
administration.
The aim of this study was therefore to couple 15d-PGJ2 to HSC-selective drug
carriers and study the uptake and pharmacological effects within the target cells. Two




Human Serum Albumin (HSA) was purchased from the central laboratory of the blood
transfusion services (Sanquin Blood Supplies, Amsterdam, The Netherlands). 15-deoxy-ǻ12,14-
Prostaglandin J2 (15d-PGJ2) was purchased from ITK Diagnostics (Uithoorn, The Netherlands). All
other chemicals used were of analytical grade.
Animals
Male Wistar rats (Harlan, outbred strain, Horst, The Netherlands) were housed under standard
laboratory conditions and had free access to food and water. This study was performed in accordance
with ethical regulations imposed by Dutch legislation.
Human liver tissue
Human liver tissue was obtained from redundant parts of donor livers after reduced-size liver
transplantation. Cirrhotic human livers were obtained from patients undergoing liver transplantation.
The use of human liver tissue was approved by the Medical Ethical Committee of the University
Medical Centre Groningen (UMCG), The Netherlands.
Synthesis
M6P-HSA: HSA was modified with mannose 6-phosphate groups as described earlier to
obtain the drug carrier M6P-HSA 3,7. The monomeric fraction was separated from the dimeric and
polymeric fraction by size-exclusion chromatography on a HiLoad 16/60 Superdex 200 column (GE
Healthcare, Uppsala, Sweden).
pPB-HSA: The cyclic peptide C*SRNLID*C was prepared by Ansynth Service BV
(Roosendaal, The Netherlands) and covalently coupled to HSA according to Beljaars et al 5.
pPB-HSA versus M6P-HSA
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Conjugation of 15d-PGJ2 to the carrier: The carboxylic group of 15d-PGJ2 (10 mg dissolved in
150 μl Dimethyl Formamid [DMF]) was activated with 11.7 mg N,N-Dicyclohexylcarbodiimide (DCC,
Sigma, St. Louis, MO, USA) dissolved in 80 μl DMF and stirred for 1 hour (RT). This 15d-PGJ2/DCC
solution was subsequently added to 20 mg M6P-HSA or pPB-HSA (dissolved in PBS, 4 mg/ml) and
the mixture was stirred at RT during 16 hours. The mixtures were extensively dialyzed (Slide-A-Lyzer
10K, Pierce Biotechnology, Rockford, IL, USA) against milliQ water at 4 °C to remove all low molecular
weight compounds (including excess of uncoupled 15d-PGJ2) and the conjugates were lyophilized and
stored at -20 °C. Six molecules of 15d-PGJ2 were coupled to M6P-HSA and 8 molecules of 15d-PGJ2
were coupled to pPB-HSA, as measured by 15d-PGJ2 correlate-EIA kit (Assay Designs, Ann Arbor,
Michigan, USA).
Rat hepatic stellate cell isolation
Primary HSC were isolated from livers of male Wistar rats (±500 g, Harlan, outbred strain)
according to Geerts et al 20. Briefly, the livers were digested with collagenase P, DNAse (both Roche
Diagnostics, Indianapolis, IN, USA) and pronase E (Merck, Darmstadt, Germany). After separation of
the HSC from other hepatic cells by density-gradient centrifugation, the HSC were collected at the top
of a 12% Nycodenz-solution. Subsequently, the cells were cultured in DMEM (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal calf serum (FCS), and incubated in a 5% CO2 humidified
atmosphere at 37 °C. Cells cultured for 10 days were used for further experiments. At this time point,
all cells have the phenotype of activated HSC 21. The phenotype of the HSC was routinely evaluated
by microscopy and checked for the presence of α-Smooth Muscle Actin, a marker for activated HSC,
by immunohistochemical methods.
Binding to HSC
To determine the specific binding of the conjugate to rat HSC, binding assays were performed
7 with 125I-15d-PGJ2-M6P-HSA and 125I-15d-PGJ2-pPB-HSA, labelled according to Mather and Ward 22.
100,000 Cells (10 days after isolation) were grown in a 6 well-plate and pre-incubated with 1% Bovine
Serum Albumin (BSA) in DMEM to block non-specific binding. HSC were then incubated at 37°C with
100,000 cpm of labelled conjugate in DMEM with 0.2% BSA. Furthermore, specific binding of the
conjugates was assessed by co-incubating the cells with HSA, M6P-HSA, pPB-HSA (all 1 mg/ml) or
Polyinosinic Acid (PIA, 10 μg/ml). After 2 hours, cells were washed with PBS and the cell-associated
radioactivity was measured on a γ-counter (Riastar, Packard instruments, Palo Alto, USA).
Biological effects on HSC.
HSC (day 7 after isolation; 5,000/well) were incubated in a 96-well plate for 24 hours in 200 μl
medium with serum, then washed with serum-free medium and incubated for an additional 24 hours in
200 μl medium with or without 10% FCS. Subsequently, 15d-PGJ2, 15d-PGJ2-M6P-HSA, M6P-HSA,
15d-PGJ2-pPB-HSA or pPB-HSA were added in increasing concentrations and the cells were
incubated with and without 10% FCS for another 18 hours. Alamar blue (20 μl, Serotec, Oxford, UK)
was added and the cells were incubated for an additional 24 hours (i.e. final analysis of HSC at day
10 after isolation). The conversion of the Alamar blue redox indicator by the metabolic activity of the
cells reflects the number of cells (i.e. net result of proliferation and apoptosis) present in each well. The




To induce liver fibrosis, male Wistar rats (220-240 g) were subjected to bile duct ligation (BDL)
as described by Kountouras et al. 24. The rats were used for further experiments after ten days after
ligation, (BDL-10d), when HSC are activated, but fibrosis is not excessive yet.
Organ distribution
Organ distribution experiments were performed in BDL-10d rats. Animals were injected i.v.
with a tracer dose of 125I-HSA, 125I-15d-PGJ2-M6P-HSA or 125I-15d-PGJ2-pPB-HSA (1,000 000 cpm per
rat, n=3) under anaesthesia. Fifteen minutes after injection, the animals were sacrificed by heart
puncture. The organs were removed and the radioactivity in each organ was measured with a γ-
counter (Packard instruments). The total radioactivity measured in the total organ was corrected for
the blood derived radioactivity according to standard procedures 4.
Hepatic localization
Anaesthetized BDL-10d rats were injected i.v. with 2 mg/kg 15d-PGJ2-M6P-HSA or 15d-PGJ2-
pPB-HSA. Fifteen minutes after administration, the rats were sacrificed and sections of the liver were
frozen in isopentane (-80 °C) and stored until immunohistochemical examination.
Immunohistochemical stainings
Acetone-fixed cryostat sections (4 μm) of liver sections were double stained for the presence
of the carrier with a antibody against HSA (MP Biomedicals, Irvine, CA, USA) together with an
antibody specific for either the Kupffer cell (ED2, Serotec), Endothelial cell (RECA1, Serotec) or HSC
(Desmin and Glial Fibrilarry Acid Protein [GFAP] simultaneously, both Sigma) 3.
The double stained sections were quantified by two independent observers (10 fields with
200X magnification per quantification). The total number of double positive cells (HSA and hepatic cell
type marker positive) was counted and related to the total number of HSA-positive cells. Rat receiving
15d-PGJ2-pPB-HSA showed a faint staining in hepatocytes, yet discrimination between positive and
negative cells was difficult. We therefore counted only the non-parenchymal cells.
To detect the target receptor in human tissue, acetone-fixed cryostat sections (4 μm) of human
liver sections were stained with goat polyclonal antibodies directed against the IGF-II/M6P-receptor or
PDGF-ȕ receptor (both Santa Cruz Biotechnology Santa Cruz, CA, USA).
Statistics
Results are expressed as +/- SEM. Statistical analysis was performed by two tailed Student’s





Radioactive binding studies with 125I-labeled 15d-PGJ2-M6P-HSA and 15d-
PGJ2-pPB-HSA were conducted to assess and compare the interaction of these
conjugates with activated rat HSC.
Studies with both conjugates showed significant binding to HSC after
incubation (= control situation). To assess the specificity of this cellular binding, we
examined whether M6P-HSA, HSA, pPB-HSA (all 1 mg/ml) and Polyinosinic Acid
(PIA, 10 μg/ml) were able to compete with this interaction. PIA is a well known
antagonist of scavenger receptors due to its polyanionic character 25. Because of the
coupling of approximately 33 M6P molecules to HSA, the net negative charge of the
molecule is increased. Therefore, scavenger receptor uptake might play a role in the
uptake by HSC.
Figure 1: Binding of 125I-15d-PGJ2-M6P-HSA (closed bars) and 125I-15d-PGJ2-pPB-HSA (open bars) to
cultures of rat HSC. The effect of co-incubation with excess amounts of several receptor agonist and
HSA was measured to asses receptor specificity. The results are expressed as the mean ± SEM (* = p
< 0.05; n.d. = not determined).
In Figure 1 it can be seen that binding of 125I-15d-PGJ2-M6P-HSA to HSC was
significantly reduced by 81 ± 5% (P<0.05) after co-incubation with M6PHSA. Co-
incubation with PIA resulted in a reduction of cellular binding by 70 ± 10% (P<0.05).
In contrast, preincubation with HSA only mildly affected the binding of 125I-15d-PGJ2-
M6P-HSA to the HSC. This indicates that binding to target cells is mediated by
specific receptors, but next to the IGF-II/M6P receptor, the scavenger receptor on
HSC is involved in the binding and uptake of this M6P-HSA conjugate.
The binding of 125I-15d-PGJ2-pPB-HSA to HSC was significantly reduced by
66 ± 10% by an excess of pPB-HSA compared with the control incubations, whereas
preincubation with neither HSA, M6P-HSA nor PIA did affect the binding of 125I-15d-






















PGJ2-pPB-HSA to the HSC (P<0.05). These studies show that 125I-15d-PGJ2-pPB-
HSA binds to HSC via specific receptors not involving the scavenger receptors. In
this respect, both constructs differ profoundly.
The biological effects on HSC
We examined the effects of 15d-PGJ2 in its free form and conjugated to M6P-
HSA or pPB-HSA on the viability in cell cultures of primary isolated rat HSC. The
influence of serum was also tested since serum components like albumin are known
to affect the bioactivity of prostaglandins19. The addition of native 15d-PGJ2 to cells
grown without FCS caused a significant and dose-dependent decline in viability (75%
reduction at 20 μM 15d-PGJ2, Figure 2A). Addition of 10% FCS completely abolished
this reduction in HSC viability (0% reduction at 20 μM 15d-PGJ2, Figure 2A).
Figure 2: Effect of different compounds on the viability of isolated activated HSC. A: 15d-PGJ2, B:
15d-PGJ2-M6P-HSA and the carrier M6P-HSA alone, C: 15d-PGJ2-pPB-HSA and the carrier pPB-HSA
alone. The experiments were performed under serum starvation (closed bars) or in the presence of
10% FCS (open bars). The estimated concentration of 15d-PGJ2 coupled to M6P-HSA (6 molecules)
or pPB-HSA (8 molecules) is depicted as well as the protein concentration of both conjugates. The
control cells (incubated with vehicle) are set at 100% viability and control wells without cells are set as
0% viability. The results are expressed as the mean ± SEM (n=3, * = p < 0.05).
Subsequently, we examined the effect of both conjugates on HSC. Without
FSC, the conjugates induced a dose-dependent reduction in the viability of HSC
starting at a concentration of 25 μg/ml 15d-PGJ2-M6P-HSA (corresponding with 1.9
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PGJ2). In the presence of 10% FCS, both conjugates were still able to reduce the cell
number, although the dose-response curve was somewhat shifted to the right (Figure
2B, 69 % reduction at 250 μg/ml 15d-PGJ2-M6P-HSA; Figure 2C, 81 % reduction at
250 μg/ml 15d-PGJ2-pPB-HSA). Both carriers alone (250 μg/ml of M6P-HSA and
pPB-HSA) induced no effect at all on cell viability, either with or without FCS (Figure
2B and C).
The distribution in vivo in fibrotic rats
The organ distribution of HSA, 15d-PGJ2-M6P-HSA and 15d-PGJ2-pPB-HSA
was studied in BDL rats, 10 days after induction of the disease. Fifteen minutes after
i.v. administration, both 125I-15d-PGJ2-M6P-HSA and 125I-15d-PGJ2-pPB-HSA
accumulated significantly in the livers (86% and 63% of the dose respectively),
leaving little conjugate in the blood (3 % and 16 % respectively). Less than 3% of the
administrated 125I-15d-PGJ2-M6P-HSA and only 7% of the administrated dose of 125I-
15d-PGJ2-pPB-HSA was taken up in other organs and tissues such as the kidney,
heart, lung and spleen (Figure 3). In contrast, organ distribution studies of 125I-HSA in
BDL-10d rats revealed that 57% of the injected dose was still in the blood 15 minutes
after injection and less than 8% of the injected dose was associated with other
organs (Figure 3). In conclusion, these data indicate a rapid and almost complete
targeting of both conjugates to the fibrotic liver.
Figure 3: Quantitative analysis of in vivo distribution of 125I-labeled proteins (15d-PGJ2-M6P-HSA,
15d-PGJ2-pPB-HSA and HSA) 15 minutes after i.v. injection in fibrotic rats (BDL day 10).
The hepatic localization in vivo in fibrotic rats
To determine the cell-specificity of 15d-PGJ2-M6P-HSA and 15d-PGJ2-pPB-
HSA within the diseased liver, we injected BDL-10d rats with the conjugates and
examined the intrahepatic distribution immunohistochemically. Double-staining of
liver sections with an antibody directed against HSA combined with antibodies























directed against different markers for hepatic cells revealed the cellular localization of
the conjugate. 15d-PGJ2-M6P-HSA was clearly taken up by non-parenchymal cells.
Quantitative evaluation by counting double positive cells showed that 64 % of the
double positive cells could be identified as HSC (Table 1, Figure 4). Also Kupffer cells
displayed substantial uptake of the M6P-conjugate (39 %), whereas endothelial cell-
uptake was low (7 %, Table 1). Quantitative evaluation of the cellular distribution of
15d-PGJ2-pPB-HSA revealed that 57 % of the double positive non-parenchymal cells
were identified as HSC (Table 1, Figure 4), whereas 24 % and 32 % of the HSA-
positive cells were identified as Kupffer cells and endothelial cells respectively (Table
1). Hepatocytes also contributed to the uptake 15d-PGJ2-pPB-HSA in the fibrotic
liver, but because of the faint non-localized staining in these cells, discrimination
between positive and negative cells was difficult. Therefore, the scoring procedure
did not allow good quantification of this uptake.
Table 1: Estimation of the intrahepatic distribution of 15d-PGJ2-M6P-HSA and 15d-PGJ2-pPB-HSA in
10d-BDL fibrotic rat livers, 15 minutes after injection. The number of double-stained positive non-
parenchymal cells was related (in percentage) to the total number of cells that are stained positive for





Hepatic Stellate Cells (%) 64 ± 5 57 ± 7
Kupffer Cells (%) 39 ± 3 24 ± 8
Endothelial Cells (%) 7 ± 5 32 ± 7
Figure 4: Immunohistochemical double stainings of 15d-PGJ2-M6P-HSA (A) and 15d-PGJ2-pPB-HSA
(B) with an antibody directed against HSA together with HSC-specific antibodies (desmin and GFAP)
in BDL-10d rats, 15 minutes after i.v injection (magnification 200X). The inserts shows co-localization




IGF-II/M6P and PDGF-ȕ receptor staining in normal and cirrhotic human livers
Finally, we examined the expression of the designated target receptors in
healthy and cirrhotic human livers. Normal liver sections displayed a parenchymal
expression of the IGF-II/M6P-receptor, whereas cirrhotic livers displayed an
increased expression of the IGF-II/M6P-receptors in the non-parenchymal cells
(Figure 5A,D).
In normal human livers, PDGF-ȕ receptor expression was found along the
portal and central blood vessels, whereas the sinusoidal endothelium was negative.
The PDGF-ȕ receptor staining of cirrhotic human livers showed a massive increase in
its expression, mainly in the fibrous bands around the portal areas. Literature data
indicate that the activated myofibroblasts are responsible for this increased
expression 9 and our observations are in line with this (Figure 5B,E).
Figure 5: Immunohistochemical staining of healthy human liver (A, D; magnification 100X) and
cirrhotic liver (B, E; magnification 40X) for the presence of IGFII/M6P-receptor (A, B and C) and
PDGF-ȕ receptor (D, E and F). A high magnification (C, F; magnification 400X) shows that the

















In this study, we compared two HSC-specific carries for their ability to deliver
15d-PGJ2 to the fibrogenic cells in the liver. The first carrier, M6P-HSA, binds
specifically to the IGF-II/M6P-receptor found on activated HSC 3,6. The second
carrier, pPB-HSA, can bind to the PDGF-ȕ receptor which is strongly increased on
the cell-surface of activated HSC 5,9. In both carriers, HSA is applied as the core
protein, in which the free primary amine group (İNH2) of lysine is coupled to the
carboxylic acid group (COOH) of 15d-PGJ2.
After coupling of 15d-PGJ2 to the carriers, the formed conjugates were still
able to bind to HSC. This binding was inhibited by preincubating the cells with the
carrier alone and not by HSA, indicating that this binding was specific. However,
preincubation with PIA, a known blocker for the scavenger receptor class A 26,
strongly reduced the binding of 15d-PGJ2-M6P-HSA to the cells. Activated HSC are
known to express both IGF-II/M6P and scavenger class B receptors 6,27. However,
the profound inhibitory effects of PIA (80% reduction) suggests that not scavenger
receptor class B, but rather class A contributes to this accumulation 26. This
scavenger receptor class A has not yet been identified on activated HSC 25, but our
results warrant further exploration of these receptors on HSC. In contrast, binding of
15d-PGJ2-pPB-HSA to cultured HSC was not affected by PIA, suggesting that
scavenger receptors are not involved in the binding of pPB-HSA to HSC. Moreover,
preincubation with M6P-HSA showed that 15d-PGJ2-pPB-HSA was not interacting
with any of the binding domains of the M6P-carrier.
Viability studies showed that both conjugates were able to effectively reduce
the viability of HSC in vitro. This demonstrated that after coupling, 15d-PGJ2
maintained its pharmacologic activity. This is an important observation because the
amide bond formed between the prostaglandins and lysine groups within HSA may
not be cleaved by intracellular proteases, yielding in the release of 15d-PGJ2-lysine
within the cells. Apparently this does not seriously affect the biological activity of this
compound. Also in the presence of serum, both conjugates effectively lowered the
viability of the cells. Serum completely blocked the effect of free 15d-PGJ2
demonstrating that the uptake and release of targeted 15d-PGJ2 occurs via a
different route than in case of free 15d-PGJ2.
Measurements of the amount of 15d-PGJ2 coupled to both carriers revealed
that 15d-PGJ2-pPB-HSA contained approximately 8 molecules of 15d-PGJ2, whereas
15d-PGJ2-M6P-HSA contained approximately 6 molecules of 15d-PGJ2. Maybe
because of this higher drug load, 15d-PGJ2-pPB-HSA was a more potent reducer of
the viability of cultured HSC than 15d-PGJ2-M6P-HSA. The difference in amount of
15d-PGJ2 molecules coupled could be a result of the amount of homing domains
(M6P or pPB) coupled to the HSA backbone. Recent studies revealed that 28 M6P
pPB-HSA versus M6P-HSA
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molecules were chemically coupled to lysine groups to form the M6P-HSA carrier 7,
whereas 15 pPB molecules were coupled to create the pPB-HSA carrier 5 leaving
more binding sites available for coupling of 15d-PGJ2 compared to M6P-HSA.
Distribution studies with 15d-PGJ2-M6P-HSA and 15d-PGJ2-pPB-HSA in
fibrotic rats revealed an almost complete targeting to the liver (86 % and 63% of the
injected dose respectively) with no significant uptake elsewhere in the body, whereas
HSA remained in the blood with almost no liver accumulation.
Analysis of the intrahepatic localization of 15d-PGJ2-M6P-HSA demonstrated a
non-parenchymal distribution pattern. This construct predominantly accumulated in
the HSC (64%) and Kupffer cells (39%). The high accumulation of the M6P-conjugate
in Kupffer cells is probably a direct effect of the net negatively charged protein
backbone of the construct which is recognized by scavenger receptors (both class A
and B) on these Kupffer cells 26.
In contrast, intrahepatic distribution studies of 15d-PGJ2-pPB-HSA showed
parenchymal as well as non-parenchymal uptake. Hepatocyte uptake was probably
relatively low, reflected by the faint staining and could therefore not be quantified.
The non-parenchymal delivered conjugate predominantly accumulated in the HSC
(57%) with some accumulation in the Kupffer cells and endothelial cells. It is likely
that the pPB-conjugate follows a similar route as the growth factor PDGF-BB 5, which
is taken up by hepatocytes after opsonization by Į2-macroglobulin 28.
The M6P-HSA carrier has already been tested in several in vivo studies
exploring the effect of HSC-targeted drugs. Next to 15d-PGJ2, other drugs such as
pentoxyfilline, doxorubicin and mycophenolic acid have been selectively delivered to
the HSC during fibrosis. In all cases, significant pharmacological effects in bile duct
ligated rats have been found. However, the fibrotic process was not completely
resolved and much effort has yet to be undertaken 8,29,30.
The PDGF-ȕ receptor is involved in the progression of fibrotic diseases in a
variety of organs including lung, kidney, liver, skin and intestine 31 and this receptor is
increased in the fibroblast-like cells during fibrosis 9,10,32,33. Also the IGF-II/M6P
receptor is increased during several fibrotic diseases 6,34. Although much less is
known about its expression profile during several diseases, in both cases, blockade
of the receptor might be beneficial. So drug carriers may contribute to the
therapeutical effects of the conjugate. Both carriers seem therefore applicable for the
purpose of delivery drugs to the most pivotal cells during fibrosis, yet each carrier has
its own advantage and disadvantage.
In summary, these studies show specific binding of two HSA-selective carriers
in cultures of HSC. The 15d-PGJ2 coupled to M6P-HSA or to pPB-HSA was clearly
pharmacologically active in vitro and both conjugates rapidly accumulated in vivo in
the fibrotic liver. Receptor interactions differ between both targeted constructs,
Chapter 7
118
leading to differences in the cellular distribution pattern within the liver (Figure 4,
Table 1), Nevertheless, in both cases, the HSC is the main targeted cell. The
coupling of 15d-PGJ2 to drug carriers clearly improves the pharmacokinetic profile of
this prostaglandin and enhanced effects in the presence of serum can be
demonstrated. In view of the antifibrotic activities of this prostaglandin, these
constructs may be a valuable tool to attenuate the fibrogenic process within the liver.
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SUMMARY
This thesis describes the delivery of apoptosis-inducing compounds to the
Hepatic Stellate Cell (HSC) during liver fibrosis. HSC play a pivotal role in the
fibrogenic process, which is a response to chronic liver injury. This cell starts to
proliferate and accumulate within the injured liver in order to regulate tissue repair.
During this activation process, increased amounts of extra cellular matrix
components and inhibitors of matrix degradation are produced by these HSC and
after chronic activation, the excessive matrix production will strongly affect the liver
homeostasis 1,2. Up till now, no effective therapy to treat liver fibrosis has reached the
clinic, leaving liver transplantation as the only option left.
Importantly, animal model studies revealed that the fibrotic process is
reversible. Rats with advanced liver fibrosis showed spontaneous resolution of
fibrotic scar tissue after withdrawal of the damaging stimulus 3. Even after established
nodular cirrhosis, a near complete resolution of liver fibrosis was found after
terminating the injury 4. The resolution was accompanied by the loss of activated
HSC via spontaneous apoptosis. This suggests that therapeutically inducing HSC
apoptosis during fibrosis might accelerate restoration of the normal liver morphology
3,5,6
.
However, the systemic use of apoptosis-inducing agents is likely to be
associated with numerous side effects. Cell-selectivity of the drug is therefore crucial
in this strategy. The specific delivery of appropriate drugs to the HSC may therefore
be a relevant option for the treatment of liver fibrosis. Drug targeting technology
largely alters the pharmacokinetic profile of a drug. If a proper homing deice is
employed, it results in an accumulation of the drug at a specific site in the body, while
limiting the adverse effects elsewhere.
In chapter 1 the aim of the present thesis is presented. Chapter 2 reviews the
role of apoptosis in liver fibrosis. The pathophysiology of liver fibrosis is described
and potential apoptosis-regulating drugs are discussed, including their safety
concerns. It is argued that a possible way to overcome these problems may be to
specifically target the selected drugs to HSC. This approach may lead to a novel
treatment of liver fibrosis.
Recent publications show the ability of Gliotoxin, a fungal metabolite (GTX), to
induce apoptosis in HSC. Not only in the carbon tetrachloride model, but also in the
thioacetamide model of liver fibrosis, significant in vivo effects of GTX were found 7,8.
However, the effects of GTX on Kupffer and liver endothelial cells were not studied in
any of these reports. Therefore, we examined this. Chapter 3 describes the effect of
GTX on not only the HSC, but on all cells in the liver assessed with liver slices. These
slices, obtained from healthy and fibrotic rat livers showed a strong apoptotic
response after incubation with GTX. Quantitative real-time PCR and
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(immuno)histochemical staining revealed that all cells in the liver (HSC, Kupffer cells,
endothelial cells and hepatocytes) were affected by GTX incubation. This
emphasized the necessity to target GTX to the HSC. In chapter 4 this targeted
approach is explored. GTX was coupled to M6P-HSA, a HSC-selective carrier 9,10.
This GTX-M6P-HSA conjugate was able to induce apoptosis in cultures of human
myofibroblasts and in fibrotic rat liver slices. In addition, this conjugate was able to
bind specifically to rat HSC. The in vivo targeting experiment showed that GTX-M6P-
HSA as well as untargeted GTX was able to reduce the expression of Į-SMA, a
marker for activated HSC, at the mRNA and the protein level. In addition, GTX
affected hepatocyte functioning as reflected by a significant reduced PAS staining
and increased serum AST (aspartate aminotransferase) levels. Hepatocytes rapidly
respond to stress or injury by activation of glycogenolysis leading to a reduced
glycogen content which can be demonstrated by PAS staining. An increase in serum
AST levels is associated with hepatocytes damage 11. Importantly, GTX-M6P-HSA
did not affect these parameters, while clearly it reduced the expression of Į-SMA, a
marker for activated HSC. These results indicate that a targeted approach for GTX
may provide a novel treatment strategy for liver fibrosis.
Prostaglandins are important mediators of inflammation. They tightly control
inflammation responses and tissue repair mechanisms. The biosynthesis of
prostaglandins is regulated by two cyclooxygenase (COX) enzymes. COX1 is
constitutively expressed, whereas COX2 is highly inducible and expressed in many
cells after cellular activation. COX-2 activity is observed in both Kupffer cells (KC)
and Hepatic Stellate Cells (HSC) during liver fibrosis 12-15. COX-2 activity plays a
significant role in the control of several, sometimes opposite, processes during
fibrosis, and only a cell-selective intervention may lead to the unravelment of the role
of COX-2 in a particular cell type in vivo. In a study described in Chapter 5 we
explored the targeted delivery of the selective COX2 inhibitor niflumic acid (NFA)
coupled to M6P-HSA. This study showed that the delivery NFA to HSC resulted in an
increase in collagen type I and III deposition within the liver. These results implicate
an important role for COX2-derived prostaglandins in the control of HSC activity
during fibrogenesis.
One of the end products of the COX2-dependent biosynthesis of
prostaglandins is 15-deoxy-Δ12,14-Prostaglandin J2 (15d-PGJ2). This cyclopentanone
exhibits several effects including growth arrest, induction of apoptosis in different cell
types and suppression of macrophage activation 16-18. Recently, it was shown that
this prostaglandin can induce apoptosis of human hepatic myofibroblasts (hMF) 19.
Sub-apoptotic concentrations of 15d-PGJ2 strongly inhibited the proliferation of hMF
and reduced the expression of interstitial collagens in vitro 20,21. However, the broad
and unspecific distribution profile of these lipophilic prostaglandins makes them
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unsuitable for systemic application. They are not only taken up by many cells, rapidly
metabolized in plasma, but also excreted in the urine, leading to a short half life in the
bloodstream combined with a potential risk of adverse effects 22. Chapter 6 explores
the effects of 15d-PGJ2 coupled to the HSC-selective carrier M6P-HSA in vitro and in
vivo in rats with liver fibrosis. The construct reduced proliferation and induced
apoptosis in human hepatic myofibroblasts in vitro. In addition, the conjugate showed
binding to isolated rat HSC and exhibited selective and rapid accumulation in the liver
in vivo. Effect studies in fibrotic rats with 15d-PGJ2 and 15d-PGJ2-M6P-HSA showed
a reduction in desmin-positive cells induced by both administered forms of 15d-PGJ2,
but only the conjugate was able to reduce procollagen 1α1 mRNA levels.
In recent years, three different HSC-selective carrier systems have been
developed 9,23,24. This thesis explores the use of two of them. The first system uses
the sugar mannose-6-phosphate which is coupled to the protein human-serum-
albumin to form M6P-HSA 9,10 and neoglycoprotein is taken up by the IGF-II/M6P-
receptor expressed by HSC 25. As indicated, chapter 4, 5 and 6 outline the data
obtained with this carrier.
The second HSC-delivery system contains small cyclic peptides that mimic the
binding site of Platelet Derived Growth Factor BB to its PDGF-ȕ receptor, chemically
coupled to the protein backbone of HSA to form pPB-HSA 24. During liver fibrosis,
PDGF is the major cytokine involved in the proliferation of HSC 26,27 and the PDGF-ȕ
receptor is highly upregulated on the cell membrane of activated HSC.
In chapter 7 the two different HSC-selective carriers coupled to 15d-PGJ2
were investigated. Both conjugates showed specific binding to HSC in vitro.
However, a selective antagonist for scavenger receptors, reduced the binding of 15d-
PGJ2-M6P-HSA to HSC, revealing the involvement of scavenger receptors in the
cellular uptake. The effect of the scavenger receptor antagonist was not detected
with 15d-PGJ2-pPB-HSA, indicating that this conjugate is not interacting with
scavenger receptors on HSC. We showed that both conjugates rapidly accumulated
in the fibrotic liver in vivo. The intrahepatic distribution revealed that 15d-PGJ2-M6P-
HSA was mainly taken up by both HSC and Kupffer cells. In contrast, 15d-PGJ2-pPB-
HSA accumulated more selectively in HSC with the Kupffer cell being less involved in
the liver uptake.
Normal liver sections displayed a parenchymal expression of the IGF-II/M6P-
receptor, whereas cirrhotic livers clearly showed an increased expression of the IGF-
II/M6P-receptors in the non-parenchymal cells. The PDGF-ȕ receptor expression in
normal human livers was mainly found along the portal and central blood vessels.
Cirrhotic human livers showed a massive increase in PDGF-ȕ receptor expression,
mainly in the fibrous bands around the portal areas. Literature data indicate that the
activated myofibroblasts are responsible for this increased expression 26.
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We concluded that both carriers differ with respect to receptor specificity in
vitro, leading to differences in intrahepatic distribution during fibrosis. Nevertheless,
both carriers seem applicable for the purpose of the delivery of drugs to the most
pivotal cells during fibrosis, although each carrier has its own advantage and
disadvantage.
GENERAL DISCUSSION
The growing knowledge on the regulation of apoptosis in normal tissue and,
even more relevant, on the deregulation during several forms of diseases (i.e. several
forms of cancer) has resulted in the introduction of apoptosis-inducing drugs. These
drugs specifically target the apoptosis regulatory pathways. Some of these drugs
already entered clinical trials and may eventually alter current cancer therapy
treatment 28. Liver fibrosis, associated with loss of the control over the tissue repair
process due to excessive proliferation of activated HSC, is also a disease in which
apoptosis-inducing drugs might be beneficial. However, unrestricted apoptosis should
not occur or at least should be minimized. We therefore designed a HSC-specific
apoptosis-inducing drug conjugate and tested this conjugate in vitro and in vivo.
Although we found an induction of apoptosis in vitro in the target cells, we were not
able to find a significant apoptotic response in vivo. An explanation for this may be
that apoptosis occurred very fast, ranging from minutes to a few hours after treatment
29
, whereas we examined the effects on the fibrotic process after 24 hours. Moreover,
it has been shown that apoptotic cells are rapidly and efficiently removed by
macrophages 30 resulting in a short half-life and a narrow window for detection of the
apoptotic bodies 31. However, we did find significant beneficial effects of the targeted
drugs in the fibrotic rats: there were less HSC and a reduced hepatic collagen
synthesis.
In this thesis, the Bile Duct Ligation (BDL) model in rats 32 was used to study
the antifibrotic effect of targeted apoptosis-inducing drugs. Initially, we chose this
model because the fibrotic process in this model is rapid, though and highly
reproducible. However, the ongoing fibrotic response induced by the accumulated
bile in the bile ducts results in a pathological process in the portal area. The
conjugates that we prepared predominantly accumulate in the central to portal zone
of the liver. In addition, the effect of the targeted therapy is not directed at the
cholestasic process, but rather against the activated hepatic stellate cell, which is a
secondary response to the accumulated bile. Only a biliojejunal anastomis of these
fibrotic BDL livers can result in a complete resolution of fibrosis 33,34. Another animal
model for liver fibrosis, in which the fibrotic response occurs in the central to portal
area of the liver, would be more appropriate to test our drug delivery conjugates. In
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this respect, the CCl4 model for liver fibrosis could be a suitable model to study the
effect of drug delivery to activated HSC. Another advantage of the latter model is that
the hepatic injury that leads to liver fibrosis, can be terminated, which opens the
option to study an improvement of the resolution process of liver fibrosis. This CCl4
model is inducible in both rats and mice, and especially the mouse CCl4 model would
create an advantage for targeted therapy studies since less conjugate (prepared in a
milligram scale in our lab) will be required for these studies.
FUTURE PERSPECTIVES
This thesis shows the feasibility of drug targeting to the most relevant cell
during the progression of liver fibrosis; the HSC. Two types of carriers have been
explored (M6P-HSA and pPB-HSA) and both can be considered as promising. Each
carrier has its own advantages and disadvantages.
The M6P-HSA carrier has already been tested in several in vivo studies
exploring the effect of HSC-targeted drugs. Next to 15d-PGJ2 and gliotoxin, also
losartan, gleevec, pentoxyfilline, doxorubicin and mycophenolic acid have been
selectively delivered to the HSC during fibrosis. In all these cases, significant
pharmacological effects in bile duct ligated rats have been found. However, in none
of these studies, the fibrotic process was fully resolved. Consequently, much effort
has yet to be undertaken to increase the efficacy of this targeted treatment 35-40.
The PDGF-ȕ receptor is involved in fibrotic diseases in a variety of organs
including lung, kidney, liver, skin and intestine. As a consequence, this receptor is
increased on the myofibroblastic cells during all these different fibrotic diseases
26,27,41-43
. Therefore, the pPB-HSA carrier might serve as a cell-selective carrier not
only for liver fibrosis, but for all kinds of fibrotic diseases in which the PDGF-ȕ
receptor plays a pivotal role during the fibrotic process.
In general, drugs should contain appropriate functional groups for covalent
conjugation. Recent developments in drug-linker technologies resulted in a platinum-
based linker which allows the coupling of drugs via their aromatic nitrogens. Such
groups are present in the chemical structure of many drug molecules. This universal
linkage system (ULS) can therefore conjugate drug molecules which can not be
coupled based on the common drug coupling reactions 39. This ULS-based linker
technology therefore largely broadens the spectrum of drugs to be coupled to a
carrier.
Previously, liposomes have been used to encapsulate prostacycline and
prostaglandin E1 to prolong their circulation time and avoid their side effects 44.
These liposome-prostaglandins accumulated in the vascular lesions of hypersensitive
rats 45. Recently, liposomes have been designed that have M6P-HSA coupled to the
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liposomal surface. These M6P-HSA liposomes were taken up by HSC in vitro and in
vivo 46. Encapsulation of 15d-PGJ2 in these M6P-HSA liposomes can potentially
leads to a selective delivery to activated HSC.
The targeting techniques presented in this thesis may therefore be applicable
for a broad spectrum of drugs for different fibrotic diseases and various types of drug
carrier systems can be employed.
CONCLUSION
The work presented in this thesis describes the targeting of apoptosis-inducing
drugs to the HSC in fibrotic livers. The GTX and 15d-PGJ2 HSC-selective conjugates
that have been prepared, show rapid and complete accumulation in the fibrotic liver.
Treatment of rats with these conjugates during liver fibrosis clearly induced
pharmacologic effects on key parameters of fibrosis. It can be concluded that the
chosen targeted approach is feasible for apoptosis-inducing drugs and may provide a
relevant step in the design of a new treatment of this chronic liver disease.
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Dit proefschrift beschrijft de resultaten van experimenten waarbij getracht is
om apoptose-inducerende middelen naar de hepatische stellaat cel (HSC) in de
fibrotische lever te sturen. Deze cellen nemen tijdens bepaalde leverziekten sterk in
aantal toe en dit zorgt dan voor problemen. Apoptose, ook wel geprogrammeerde
celdood genoemd, zorgt ervoor dat de cel zichzelf uitschakelt na een beschadiging.
De dode cel wordt hierna netjes opgeruimd door macrofagen. Literatuur heeft
aangetoond dat zowel gliotoxine als 15-deoxy-Δ12,14-Prostaglandin J2 (15d-PGJ2)
apoptose van HSC kan veroorzaken. De werking van deze 2 stoffen is niet specifiek
voor de HSC, maar meerdere cellen kunnen in apoptose gaan. Het toedienen van
gliotoxine en 15d-PGJ2 zonder dat deze stoffen gericht gestuurd worden zou mogelijk
leiden tot ernstige bijwerkingen over het gehele lichaam. Een oplossing voor dit
probleem zou kunnen zijn om gliotoxine en 15d-PGJ2 specifiek af te leveren op de
plek in het lichaam waar de apoptose inducerende werking gewenst is. Dit principe,
genoemd drug-targeting, is niet nieuw. De Duitse Nobelprijswinnaar Paul Ehrlich
bedacht al rond 1900 zijn “magic bullet” theorie waarbij een medicijn specifiek een
ziekte te lijf gaat zonder bijwerkingen op andere plekken in het lichaam.
Een ziekte waarvoor tot op heden geen geschikt medicijn beschikbaar is, is
leverfibrose. Deze ziekte kan ontstaan als gevolg van langdurige leverschade, zoals
onder andere door virusinfecties (veelal hepatitis B of C), chronisch alcoholmisbruik
of geneesmiddeltoxiciteit. Tijdens dit jarenlange ziekteproces worden grote
hoeveelheden littekenweefsel (o.a. collagenen) aangemaakt door de lever (Figuur 1).
Uiteindelijk zorgt deze toename van littekenweefsel ervoor dat de leverstructuur en
functie verstoord wordt wat uiteindelijk lethaal kan worden. Het eindstadium van
leverfibrose, levercirrose, is nu alleen te behandelen met een levertransplantatie.
Figuur 1: Een gezonde humane lever (links) en een fibrotische humane lever (rechts).







De lever bestaat uit verschillende soorten cellen. Het grootste gedeelte van
deze cellen zijn de hepatocyten (voor de opname en afbraak van vele stoffen).
Daarnaast zijn er nog Kupffer cellen (lever macrofagen), endotheelcellen (bloedvat
bekleding), galgangepitheel cellen, en de eerder genoemde Hepatische Stelaat
Cellen (HSC: opslag vitamine A). Leverschade kan leiden tot beschadiging van de
hepatocyt. Als reactie op deze schade zal de hepatocyt verschillende stress signalen
afgeven naar omliggende cellen. Met name de Kupffer cel zal hierop reageren door
cytokinen en groeifactoren (signaalstoffen van het immuunsysteem) te produceren.
De afgifte van deze factoren zorgt er uiteindelijk voor dat de HSC geactiveerd raakt,
gaat prolifereren en littekenweefsel gaat aanmaken. Op zich is dit een normaal
wondhelingsproces, maar bij chronische leverschade zal dit leiden tot ophoping van
het littekenweefsel in de lever.
Figuur 2: Lichaamsverdeling van een ongekoppeld geneesmiddel (links) en een geneesmiddel
gekoppeld aan een HSC-specifieke carrier (rechts). Het vrije geneesmiddel zal zich over het gehele
lichaam verdelen (grijs), terwijl het gericht getuurde geneesmiddel specifiek ophoopt bij de HSC cellen
in de lever (grijs).
Er wordt wereldwijd veel onderzoek gedaan om een geneesmiddel te vinden
voor leverfibrose, maar tot op heden is er weinig succes geboekt. Een oorzaak
hiervoor kan zijn dat het antifibrotische middel niet in de juiste levercel komt, of
omdat er ernstige complicaties zijn. Onze aanpak in de ontwikkeling van een
antifibrotisch middel is het sturen van antifibrotische middelen naar HSC (Figuur 2),
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wat mogelijk is geworden door de recente ontwikkeling van geneesmiddeldragers
(“carriers”) naar dit celtype. In dit proefschrift worden 2 HSC-specifieke carriers
gebruikt. Deze carriers binden aan celmembraan receptoren die opgereguleerd
worden tijdens de activatie van de HSC. De target receptoren zijn Insulin Like Growth
Factor II / Mannose-6-Phosphate (IGF-II/M6P) receptor, hoofdstuk 4, 5, 6 en 7, en
de PDGF-ȕ receptor, hoofdstuk 7. Door aan het eiwit Humaan Serum Albumine
(HSA) specifieke herkenningsdomeinen voor deze receptoren te koppelen ontstaat
de HSC selectieve drug-carrier M6P-HSA (voor de IGF-II/M6P receptor) of pPB-HSA
(voor de PDGF-ȕ receptor).
Hoewel er op dit moment nog geen effectieve therapie bestaat om leverfibrose
te genezen, zijn wetenschappers er wel in geslaagd om in diermodellen een
verbetering van de ziekte aan te tonen door de oorzaak van de ziekte weg te nemen.
Tijdens het hieropvolgende genezingsproces verminderde de hoeveelheid
geactiveerde HSC in de lever door apoptose (geprogrammeerde celdood). Dit
onderzoek suggereert dat door het verminderen van het aantal HSC in de fibrotische
gebieden via apoptose mogelijk leidt tot een herstel van de lever. Het doel van het
onderzoek dat in dit proefschrift beschreven staat richt zich nu dan ook op het
induceren van apoptose in HSC door middel van het selectief afleveren van
apoptose-inducerende stoffen in de geactiveerde HSC. Op deze manier zal de
geactiveerde HSC in de lever uitgeschakeld (gedood) worden om zo een verbetering
van de fibrose in de lever te krijgen. Uiteraard is het dan wel belangrijk dat andere
cellen in andere organen van het lichaam niet uitgeschakeld worden en toxische
effecten veroorzaken.
Recent onderzoek heeft aangetoond dat verschillende stoffen in staat zijn om
apoptose te veroorzaken in de geactiveerde HSC. Een van die stoffen is gliotoxine.
Deze stof, geproduceerd door een schimmel, heeft naast zijn apoptose inducerende
eigenschappen ook een werking op het immuunsysteem. Hoofdstuk 3 laat zien dat
gliotoxine zeer effectief is in HSC, maar dat ook alle andere levercellen in meer of
mindere mate worden beïnvloed door gliotoxine. Deze resultaten benadrukken dat
het belangrijk is om een toxische stof als gliotoxine gericht af te leveren in de HSC
als het in de toekomst gebruikt wordt als geneesmiddel bij patiënten met leverfibrose.
In hoofdstuk 4 wordt gliotoxine gekoppeld aan de HSC-selectieve carrier M6P-HSA.
Proefdieren met een fibrotische lever laten duidelijk zien dat zowel het HSC-
gestuurde als het vrije gliotoxine een vermindering van de leverfibrose veroorzaken.
Het vrije gliotoxine heeft echter ook ongewenste effecten op de hepatocyt, wat kan
duiden op extra leverschade. Hieruit kan geconcludeerd worden dat gliotoxine
gekoppeld aan de HSC carrier M6P-HSA te prefereren is boven het ongekoppelde
gliotoxine als mogelijk nieuwe strategie voor de behandeling van leverfibrose.
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Prostaglandines hebben een belangrijke rol in het coördineren van
immuunreacties. De productie van prostaglandines door de cel wordt gereguleerd
door cyclooxygenase (COX) enzymen. Met name COX2 heeft in dit proces een
belangrijke functie. Tijdens leverfibrose wordt het strak gecontroleerde
immuunsysteem drastisch verstoord. De verschillende levercellen spellen hierin een
belangrijke, maar soms tegenovergestelde rol. Hoofdstuk 5 laat zien dat het gericht
sturen van de COX2 remmer nifluminezuur naar de HSC zorgt voor een toename van
het fibrotische proces in de lever. Dit resultaat laat duidelijk zien dat de
prostaglandines, die door COX2 geproduceerd worden, een belangrijke schakel zijn
in de HSC respons tijdens leverfibrose.
Omdat het remmen van de prostaglandine productie in HSC negatieve
gevolgen had voor de fibrotische lever (hoofdstuk 5), zou het toevoegen van
prostaglandines aan de HSC wellicht tot een remming van het fibrotische proces
kunnen leiden. Er zijn veel verschillende soorten prostaglandines die allemaal door
het lichaam zelf gemaakt kunnen worden. Eerder onderzoek heeft aangetoond dat
15-deoxy-Δ12,14-Prostaglandin J2 (15d-PGJ2) apoptose kan veroorzaken in
geactiveerde HSC. In een lagere concentratie werd de groei van HSC en de
productie van collagenen geremd. Om optimaal gebruik te maken van deze anti-
fibrotische eigenschappen werd 15d-PGJ2 door ons in de HSC afgeleverd. De
resultaten van Hoofdstuk 6 laten duidelijk zien dat 15d-PGJ2 gekoppeld aan de HSC
carrier M6P-HSA zeer snel ophoopt in de fibrotische lever van de rat (binnen 5
minuten na injectie) en dat deze ophoping bijna volledig is (86% van de ingespoten
hoeveelheid). Effect studies laten tevens zien dat een cruciale schakel (reductie in
collageen RNA) in de productie van littekenweefsel wordt geremd. Deze resultaten
leiden tot de conclusie dat het gericht sturen van 15d-PGJ2 naar de HSC kan leiden
tot een vermindering leverfibrose.
Tot slot beschrijft hoofdstuk 7 een vergelijkend onderzoek naar de specifieke
afgifte van 15d-PGJ2 aan de HSC. Hiervoor is gebruik gemaakt van twee carriers: de
HSC-specifieke carrier pPB-HSA en de in hoofdstuk 4,5 en 6 toegepaste carrier
M6P-HSA. De verschillen in receptor specificiteit van de beide carriers leidde binnen
de fibrotische lever tot verschillen in de verdeling binnen de fibrotische lever.
Desalniettemin hoopten beide carriers zich voornamelijk op in de HSC in de
fibrotische lever. Ook werd gekeken naar de hoeveelheid van de target receptoren
(IGF-II/M6P receptor en PDGF-ȕ receptor in gezonde en fibrotische humane levers.
Duidelijk was dat beide receptoren sterk in aantal toenemen in de fibrotische lever.
Uit hoofdstuk 7 kan derhalve geconcludeerd worden dat ondanks kleine verschillen
in HSC specificiteit, beide receptoren geschikt zijn als doel receptor om 15d-PGJ2
gericht naar de humane HSC te sturen.
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Samenvattend kan geconcludeerd worden dat het mogelijk is om apoptose
inducerende geneesmiddelen specifiek af te leveren bij de HSC. Dit resulteert in een
anti-fibrotisch effect in de lever in een diermodel. Het is nog veel te vroeg om deze
HSC specifieke behandelmethode in de kliniek toe te passen, maar dit onderzoek
kan wellicht als basis dienen voor vervolgonderzoek naar de selectieve afgifte van
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Nog een paar pagina’s. Daarna is dit proefschrift echt af. Dit zijn niet de minste
bladzijden. Want onderzoek doe je niet alleen. Gelukkig niet! Dan zouden het 4 heel
saaie jaren zijn geweest. Er zijn veel mensen die een belangrijke rol hebben
gespeeld in de totstandkoming van wat je nu in de handen hebt.
Allereerst wil ik Klaas Poelstra bedanken. Je had de belangrijke taak om mijn
promotor te zijn. Ik heb veel van je gedreven manier van onderzoek doen kunnen
leren. Ondanks je drukke agenda, je benoeming tot hoogleraar en het opstarten van
je eigen bedrijf stond je ook succesvol aan het roer van de drug-targeting groep. De
maandagochtend besprekingen waren zeer aangenaam en hebben mij gescherpt in
constructief meedenken en het voeren van een wetenschappelijke discussie. Veel
beginnende problemen werden tijdens deze ochtenden door jouw scherpe blik weer
weggewerkt. Door je “open deur” beleid had je mij af en toe wel iets te vaak over de
vloer, maar je was wel altijd bereid om even mee te denken en om advies te geven.
Ontzettend bedankt voor de 4 fijne jaren dat ik in jouw groep mijn experimenten heb
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Deze bijna soms filosofische besprekingen heb ik altijd heel leerzaam gevonden.
Leonie, copromotor, ik heb zeer veel aan jou te danken. Zowel tijdens de
experimenten als in de afrondende fase van het promotietraject was jij altijd
beschikbaar om constructief mee te denken. Bedankt voor de fijne samenwerking.
Veel succes met het vervolg project.
De analisten van de fibrose groep wil ik graag bedanken voor hun inzet voor het
onderzoek. De leuke gesprekken tijdens de experimenten op de labvloer en in de
kantine hebben ervoor gezorgd dat ik met plezier naar het lab ging. Catharina, Alie,
Anne-miek en Hester, bedankt voor de talloze stelaatcel isolaties, chemische
koppelingen, dierexperimenten (dubbel)kleuringen RNA-isolaties, PCR reacties en de
vele andere experimenten. Zonder jullie waren de vele experimenten nooit gelukt. Ik
wens jullie veel succes in al jullie toekomstige werkzaamheden.
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hiervan, Genny en Peter, wil ik daarvoor graag bedanken. De rest van de humane
groep, Marieke, Inge, Annelies, Marina en Marjolein (mijn leukste [nu ex-]collega)
hebben mij perfect geholpen met het gehele slice-gebeuren. Ik denk dat ik de enige
ben die het voor elkaar heeft gekregen om een studie met ratten leverslices te
publiceren als klinische studie.
During my studies, I had the opportunity to work for 3 weeks in the lab of Sophie
Lotersztajn in Paris. I really enjoyed the time I spent in Paris. The experiments
performed, together with Boris Julien during these 3 weeks resulted in 2 submitted
articles (hopefully published articles soon).
De gehele farmacokinetiek afdeling bestaat uit meer mensen dan hierboven
genoemd zijn. De man die de gehele groep draaiende houdt (behalve als hij op
vakantie is) is Jan. Bedankt voor het geregel achter de schermen. Naast al dat
geregel had je genoeg tijd om een HPLC methode op te zetten met bomen van
pieken, die je ook nog eens op je “eigen“ manier hebt gevalideerd. Rick, naast het
echte wetenschappelijke werk, hebben we tot 2 keer toe het beste bier van de wereld
gebrouwen. Ook was er tussen de werkzaamheden door tijd om het gehele koek-
schap in de supermarkt te onderzoeken met de gangmaker als absolute winnaar.
Annemarie, na vele werkbesprekingen haal ik toch nog steeds de PNPP, phosphate
release assay en de gorrie morrie kleuring door elkaar. Heni, Jai, Asia, Teresa,
Ansar, Adriana en Janja, I really liked the time we spent outside the lab with you.
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Hans, Bert, Gillian, Ingrid, Frits en de mensen van TGM bedanken voor de gezellige
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wilde ik de 2 studenten die ik begeleid heb, Annemarie en Willie, bedanken voor hun
inzet en het werk dat ze geleverd hebben.
Naast de mensen in het lab, heb ik veel plezier beleefd met de mensen van lichting
’96 et al. Daarom wilde ik graag Rhodium, de Hond, de Joego, Mr Netjes, Annie,
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de bijnaamlozen bedanken voor de leuke skivakanties en andere groepsuitjes en het
kijken naar de vele voetbalwedstrijden. We maken er een mooi feestje van, de 17de!
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Jorden en Bas, mooi dat jullie mijn paranimfen zijn. Toen we gezamenlijk in 1990 met
de middelbare school in Kampen begonnen had ik nooit kunnen bedenken dat jullie
16 jaar later mijn paranimfen zouden zijn. Een betere vriendschap bestaat er niet. En
met Delft, Utrecht en Groningen is er volop ruimte voor afwisseling van de te plannen
weekenden.
De belangrijkste mensen om te bedanken staan helemaal aan het eind. Sander (en
Anneloes), Vincent (en Sibylle), het is fijn om goed met je broers overweg te kunnen.
Willem en Trix, jullie kan ik niet genoeg bedanken. Veel weekenden heb ik bij jullie
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jullie zoons echte Groningse stadsnomaden zijn. Bedankt voor de steun, het
vertrouwen en de mogelijkheden die jullie mij gegeven hebben.
En nu is het af!
